BE0005 TS-1/ InVivoMab anti-human LFA-1α (CD11a) mouse IgG , ,000 BE0005 TS-1/ InVivoMab anti-human LFA-1α (CD11a) mous
|
|
|
- ふさこ くぬぎ
- 5 years ago
- Views:
Transcription
1 Bio X Cell 社価格表 (2018 年 4 月 ) < 株式会社シン コーポレーション > Bio X Cell 社価格表 (2018 年 4 月 ) ご注文ごとに別途取扱手数料 (2( 万円 税別 ) を申し受けます 大学向け価格でのご購入には アカデミックプライス適用申込書のご提出が必須となります 品番クローン品名イソタイプ 容量 (mg) 大学向希望小売価格 ( 円 ) 税別 希望小売価格 ( 円 ) 税別 InVivoMAb シリーズ BE G11 InVivoMab anti-mouse CD1d (CD1.1) rat IgG2b 1 15,000 22,000 BE G11 InVivoMab anti-mouse CD1d (CD1.1) rat IgG2b 5 55,000 77,000 BE G11 InVivoMab anti-mouse CD1d (CD1.1) rat IgG2b , ,000 BE G11 InVivoMab anti-mouse CD1d (CD1.1) rat IgG2b , ,000 BE G11 InVivoMab anti-mouse CD1d (CD1.1) rat IgG2b , ,000 BE C11 InVivoMab anti-mouse CD3ε Armenian hamster IgG 1 15,000 22,000 BE C11 InVivoMab anti-mouse CD3ε Armenian hamster IgG 5 55,000 77,000 BE C11 InVivoMab anti-mouse CD3ε Armenian hamster IgG , ,000 BE C11 InVivoMab anti-mouse CD3ε Armenian hamster IgG , ,000 BE C11 InVivoMab anti-mouse CD3ε Armenian hamster IgG , , C11 f(ab')2 BE0001-1FAB Fragments InVivoMab anti-mouse CD3ε F(ab')2 fragment hamster IgG2b 5 78, , C11 f(ab')2 BE0001-1FAB Fragments InVivoMab anti-mouse CD3ε F(ab')2 fragment hamster IgG2b , , C11 f(ab')2 BE0001-1FAB Fragments InVivoMab anti-mouse CD3ε F(ab')2 fragment hamster IgG2b , , C11 f(ab')2 BE0001-1FAB Fragments InVivoMab anti-mouse CD3ε F(ab')2 fragment hamster IgG2b , ,000 BE OKT-3 InVivoMab anti-human CD3 mouse IgG2a 1 15,000 22,000 BE OKT-3 InVivoMab anti-human CD3 mouse IgG2a 5 55,000 77,000 BE OKT-3 InVivoMab anti-human CD3 mouse IgG2a , ,000 BE OKT-3 InVivoMab anti-human CD3 mouse IgG2a , ,000 BE OKT-3 InVivoMab anti-human CD3 mouse IgG2a , ,000 BE A2 InVivoMab anti-mouse CD3 rat IgG2b 1 15,000 22,000 BE A2 InVivoMab anti-mouse CD3 rat IgG2b 5 55,000 77,000 BE A2 InVivoMab anti-mouse CD3 rat IgG2b , ,000 BE A2 InVivoMab anti-mouse CD3 rat IgG2b , ,000 BE A2 InVivoMab anti-mouse CD3 rat IgG2b , ,000 BE GK1.5 InVivoMab anti-mouse CD4 rat IgG2b 1 15,000 22,000 BE GK1.5 InVivoMab anti-mouse CD4 rat IgG2b 5 55,000 77,000 BE GK1.5 InVivoMab anti-mouse CD4 rat IgG2b , ,000 BE GK1.5 InVivoMab anti-mouse CD4 rat IgG2b , ,000 BE GK1.5 InVivoMab anti-mouse CD4 rat IgG2b , ,000 BE OKT-4 InVivoMab anti-human CD4 mouse IgG2b 1 15,000 22,000 BE OKT-4 InVivoMab anti-human CD4 mouse IgG2b 5 55,000 77,000 BE OKT-4 InVivoMab anti-human CD4 mouse IgG2b , ,000 BE OKT-4 InVivoMab anti-human CD4 mouse IgG2b , ,000 BE OKT-4 InVivoMab anti-human CD4 mouse IgG2b , ,000 BE YTS 177 InVivoMab anti-mouse CD4 rat IgG2a 1 15,000 22,000 BE YTS 177 InVivoMab anti-mouse CD4 rat IgG2a 5 55,000 77,000 BE YTS 177 InVivoMab anti-mouse CD4 rat IgG2a , ,000 BE YTS 177 InVivoMab anti-mouse CD4 rat IgG2a , ,000 BE YTS 177 InVivoMab anti-mouse CD4 rat IgG2a , ,000 BE InVivoMab anti-mouse CD8α rat IgG2a 1 15,000 22,000 BE InVivoMab anti-mouse CD8α rat IgG2a 5 55,000 77,000 BE InVivoMab anti-mouse CD8α rat IgG2a , ,000 BE InVivoMab anti-mouse CD8α rat IgG2a , ,000 BE InVivoMab anti-mouse CD8α rat IgG2a , ,000 BE OKT-8 InVivoMab anti-human CD8α mouse IgG2a 1 15,000 22,000 BE OKT-8 InVivoMab anti-human CD8α mouse IgG2a 5 55,000 77,000 BE OKT-8 InVivoMab anti-human CD8α mouse IgG2a , ,000 BE OKT-8 InVivoMab anti-human CD8α mouse IgG2a , ,000 BE OKT-8 InVivoMab anti-human CD8α mouse IgG2a , ,000 BE0005 TS-1/ InVivoMab anti-human LFA-1α (CD11a) mouse IgG1 1 15,000 22,000 BE0005 TS-1/ InVivoMab anti-human LFA-1α (CD11a) mouse IgG1 5 55,000 77,000 BE0005 TS-1/ InVivoMab anti-human LFA-1α (CD11a) mouse IgG , ,000 1 ご注文ごとに別途取扱手数料 (2 万円 税別 ) を申し受けます
2 BE0005 TS-1/ InVivoMab anti-human LFA-1α (CD11a) mouse IgG , ,000 BE0005 TS-1/ InVivoMab anti-human LFA-1α (CD11a) mouse IgG , ,000 BE FD441.8 InVivoMab anti-mouse LFA-1α (CD11a) rat IgG2b 1 15,000 22,000 BE FD441.8 InVivoMab anti-mouse LFA-1α (CD11a) rat IgG2b 5 55,000 77,000 BE FD441.8 InVivoMab anti-mouse LFA-1α (CD11a) rat IgG2b , ,000 BE FD441.8 InVivoMab anti-mouse LFA-1α (CD11a) rat IgG2b , ,000 BE FD441.8 InVivoMab anti-mouse LFA-1α (CD11a) rat IgG2b , ,000 BE0006 M17/4 InVivoMab anti-mouse LFA-1α (CD11a) rat IgG2a 1 15,000 22,000 BE0006 M17/4 InVivoMab anti-mouse LFA-1α (CD11a) rat IgG2a 5 55,000 77,000 BE0006 M17/4 InVivoMab anti-mouse LFA-1α (CD11a) rat IgG2a , ,000 BE0006 M17/4 InVivoMab anti-mouse LFA-1α (CD11a) rat IgG2a , ,000 BE0006 M17/4 InVivoMab anti-mouse LFA-1α (CD11a) rat IgG2a , ,000 BE0007 M1/70 InVivoMab anti-mouse/human CD11b rat IgG2b 1 15,000 22,000 BE0007 M1/70 InVivoMab anti-mouse/human CD11b rat IgG2b 5 55,000 77,000 BE0007 M1/70 InVivoMab anti-mouse/human CD11b rat IgG2b , ,000 BE0007 M1/70 InVivoMab anti-mouse/human CD11b rat IgG2b , ,000 BE0007 M1/70 InVivoMab anti-mouse/human CD11b rat IgG2b , ,000 BE0009 M18/2 InVivoMab anti-mouse CD18 rat IgG2a 1 15,000 22,000 BE0009 M18/2 InVivoMab anti-mouse CD18 rat IgG2a 5 55,000 77,000 BE0009 M18/2 InVivoMab anti-mouse CD18 rat IgG2a , ,000 BE0009 M18/2 InVivoMab anti-mouse CD18 rat IgG2a , ,000 BE0009 M18/2 InVivoMab anti-mouse CD18 rat IgG2a , ,000 BE0011 Cy34.1 InVivoMab anti-mouse CD22 mouse IgG1 1 15,000 22,000 BE0011 Cy34.1 InVivoMab anti-mouse CD22 mouse IgG1 5 55,000 77,000 BE0011 Cy34.1 InVivoMab anti-mouse CD22 mouse IgG , ,000 BE0011 Cy34.1 InVivoMab anti-mouse CD22 mouse IgG , ,000 BE0011 Cy34.1 InVivoMab anti-mouse CD22 mouse IgG , ,000 BE0012 PC InVivoMab anti-mouse CD25 (IL-2Rα) rat IgG1 1 15,000 22,000 BE0012 PC InVivoMab anti-mouse CD25 (IL-2Rα) rat IgG1 5 55,000 77,000 BE0012 PC InVivoMab anti-mouse CD25 (IL-2Rα) rat IgG , ,000 BE0012 PC InVivoMab anti-mouse CD25 (IL-2Rα) rat IgG , ,000 BE0012 PC InVivoMab anti-mouse CD25 (IL-2Rα) rat IgG , ,000 BE0013 7D4 InVivoMab anti-mouse CD25 (IL-2Rα) rat IgM 1 15,000 22,000 BE0013 7D4 InVivoMab anti-mouse CD25 (IL-2Rα) rat IgM 5 55,000 77,000 BE0013 7D4 InVivoMab anti-mouse CD25 (IL-2Rα) rat IgM , ,000 BE0013 7D4 InVivoMab anti-mouse CD25 (IL-2Rα) rat IgM , ,000 BE0013 7D4 InVivoMab anti-mouse CD25 (IL-2Rα) rat IgM , ,000 BE0014 7G7B6 InVivoMab anti-human CD25 (IL-2Rα) mouse IgG2a 1 15,000 22,000 BE0014 7G7B6 InVivoMab anti-human CD25 (IL-2Rα) mouse IgG2a 5 55,000 77,000 BE0014 7G7B6 InVivoMab anti-human CD25 (IL-2Rα) mouse IgG2a , ,000 BE0014 7G7B6 InVivoMab anti-human CD25 (IL-2Rα) mouse IgG2a , ,000 BE0014 7G7B6 InVivoMab anti-human CD25 (IL-2Rα) mouse IgG2a , ,000 BE InVivoMab anti-mouse CD28 Syrian hamster IgG2 1 15,000 22,000 BE InVivoMab anti-mouse CD28 Syrian hamster IgG2 5 55,000 77,000 BE InVivoMab anti-mouse CD28 Syrian hamster IgG , ,000 BE InVivoMab anti-mouse CD28 Syrian hamster IgG , ,000 BE InVivoMab anti-mouse CD28 Syrian hamster IgG , ,000 BE PV-1 InVivoMab anti-mouse CD28 Armenian hamster IgG 1 15,000 22,000 BE PV-1 InVivoMab anti-mouse CD28 Armenian hamster IgG 5 55,000 77,000 BE PV-1 InVivoMab anti-mouse CD28 Armenian hamster IgG , ,000 BE PV-1 InVivoMab anti-mouse CD28 Armenian hamster IgG , ,000 BE PV-1 InVivoMab anti-mouse CD28 Armenian hamster IgG , ,000 BE FGK4.5/FGK45 InVivoMab anti-mouse CD40 rat IgG2a 1 15,000 22,000 BE FGK4.5/FGK45 InVivoMab anti-mouse CD40 rat IgG2a 5 55,000 77,000 BE FGK4.5/FGK45 InVivoMab anti-mouse CD40 rat IgG2a , ,000 BE FGK4.5/FGK45 InVivoMab anti-mouse CD40 rat IgG2a , ,000 BE FGK4.5/FGK45 InVivoMab anti-mouse CD40 rat IgG2a , ,000 BE MR-1 InVivoMab anti-mouse CD154 (CD40L) Armenian hamster IgG 1 15,000 22,000 BE MR-1 InVivoMab anti-mouse CD154 (CD40L) Armenian hamster IgG 5 55,000 77,000 BE MR-1 InVivoMab anti-mouse CD154 (CD40L) Armenian hamster IgG , ,000 BE MR-1 InVivoMab anti-mouse CD154 (CD40L) Armenian hamster IgG , ,000 BE MR-1 InVivoMab anti-mouse CD154 (CD40L) Armenian hamster IgG , ,000 BE0019 MB23G2 (HB220) InVivoMab anti-mouse CD45RB rat IgG2a 1 15,000 22,000 2 ご注文ごとに別途取扱手数料 (2 万円 税別 ) を申し受けます
3 BE0019 MB23G2 (HB220) InVivoMab anti-mouse CD45RB rat IgG2a 5 55,000 77,000 BE0019 MB23G2 (HB220) InVivoMab anti-mouse CD45RB rat IgG2a , ,000 BE0019 MB23G2 (HB220) InVivoMab anti-mouse CD45RB rat IgG2a , ,000 BE0019 MB23G2 (HB220) InVivoMab anti-mouse CD45RB rat IgG2a , ,000 BE B6H12 InVivoMab anti-human CD47 mouse IgG1 1 15,000 22,000 BE B6H12 InVivoMab anti-human CD47 mouse IgG1 5 55,000 77,000 BE B6H12 InVivoMab anti-human CD47 mouse IgG , ,000 BE B6H12 InVivoMab anti-human CD47 mouse IgG , ,000 BE B6H12 InVivoMab anti-human CD47 mouse IgG , ,000 BE YN1/1.7.4 InVivoMab anti-mouse CD54 (ICAM-1) rat IgG2b 1 15,000 22,000 BE YN1/1.7.4 InVivoMab anti-mouse CD54 (ICAM-1) rat IgG2b 5 55,000 77,000 BE YN1/1.7.4 InVivoMab anti-mouse CD54 (ICAM-1) rat IgG2b , ,000 BE YN1/1.7.4 InVivoMab anti-mouse CD54 (ICAM-1) rat IgG2b , ,000 BE YN1/1.7.4 InVivoMab anti-mouse CD54 (ICAM-1) rat IgG2b , ,000 BE R6-5-D6 InVivoMab anti-human CD54 (ICAM-1) mouse IgG2a 1 15,000 22,000 BE R6-5-D6 InVivoMab anti-human CD54 (ICAM-1) mouse IgG2a 5 55,000 77,000 BE R6-5-D6 InVivoMab anti-human CD54 (ICAM-1) mouse IgG2a , ,000 BE R6-5-D6 InVivoMab anti-human CD54 (ICAM-1) mouse IgG2a , ,000 BE R6-5-D6 InVivoMab anti-human CD54 (ICAM-1) mouse IgG2a , ,000 BE0021 Mel-14 InVivoMab anti-mouse L-Selectin (CD62L) rat IgG2a 1 15,000 22,000 BE0021 Mel-14 InVivoMab anti-mouse L-Selectin (CD62L) rat IgG2a 5 55,000 77,000 BE0021 Mel-14 InVivoMab anti-mouse L-Selectin (CD62L) rat IgG2a , ,000 BE0021 Mel-14 InVivoMab anti-mouse L-Selectin (CD62L) rat IgG2a , ,000 BE0021 Mel-14 InVivoMab anti-mouse L-Selectin (CD62L) rat IgG2a , ,000 BE0022 FR70 InVivoMab anti-mouse CD70 rat IgG2b 1 15,000 22,000 BE0022 FR70 InVivoMab anti-mouse CD70 rat IgG2b 5 55,000 77,000 BE0022 FR70 InVivoMab anti-mouse CD70 rat IgG2b , ,000 BE0022 FR70 InVivoMab anti-mouse CD70 rat IgG2b , ,000 BE0022 FR70 InVivoMab anti-mouse CD70 rat IgG2b , ,000 BE0023 OKT9 InVivoMab anti-human CD71 mouse IgG1 1 15,000 22,000 BE0023 OKT9 InVivoMab anti-human CD71 mouse IgG1 5 55,000 77,000 BE0023 OKT9 InVivoMab anti-human CD71 mouse IgG , ,000 BE0023 OKT9 InVivoMab anti-human CD71 mouse IgG , ,000 BE0023 OKT9 InVivoMab anti-human CD71 mouse IgG , ,000 BE A1 InVivoMab anti-mouse CD80 (B7-1) Armenian hamster IgG2 1 15,000 22,000 BE A1 InVivoMab anti-mouse CD80 (B7-1) Armenian hamster IgG2 5 55,000 77,000 BE A1 InVivoMab anti-mouse CD80 (B7-1) Armenian hamster IgG , ,000 BE A1 InVivoMab anti-mouse CD80 (B7-1) Armenian hamster IgG , ,000 BE A1 InVivoMab anti-mouse CD80 (B7-1) Armenian hamster IgG , ,000 BE0025 GL-1 InVivoMab anti-mouse CD86 (B7-2) rat IgG2a 1 15,000 22,000 BE0025 GL-1 InVivoMab anti-mouse CD86 (B7-2) rat IgG2a 5 55,000 77,000 BE0025 GL-1 InVivoMab anti-mouse CD86 (B7-2) rat IgG2a , ,000 BE0025 GL-1 InVivoMab anti-mouse CD86 (B7-2) rat IgG2a , ,000 BE0025 GL-1 InVivoMab anti-mouse CD86 (B7-2) rat IgG2a , ,000 BE0026 M290 InVivoMab anti-mouse CD103 rat IgG2a 1 15,000 22,000 BE0026 M290 InVivoMab anti-mouse CD103 rat IgG2a 5 55,000 77,000 BE0026 M290 InVivoMab anti-mouse CD103 rat IgG2a , ,000 BE0026 M290 InVivoMab anti-mouse CD103 rat IgG2a , ,000 BE0026 M290 InVivoMab anti-mouse CD103 rat IgG2a , ,000 BE0027 M/K-2.7 InVivoMab anti-mouse CD106 (VCAM-1) rat IgG1 1 15,000 22,000 BE0027 M/K-2.7 InVivoMab anti-mouse CD106 (VCAM-1) rat IgG1 5 55,000 77,000 BE0027 M/K-2.7 InVivoMab anti-mouse CD106 (VCAM-1) rat IgG , ,000 BE0027 M/K-2.7 InVivoMab anti-mouse CD106 (VCAM-1) rat IgG , ,000 BE0027 M/K-2.7 InVivoMab anti-mouse CD106 (VCAM-1) rat IgG , ,000 BE0028 HK5.3 InVivoMab anti-mouse ICOSL (CD275) rat IgG2a 1 15,000 22,000 BE0028 HK5.3 InVivoMab anti-mouse ICOSL (CD275) rat IgG2a 5 55,000 77,000 BE0028 HK5.3 InVivoMab anti-mouse ICOSL (CD275) rat IgG2a , ,000 BE0028 HK5.3 InVivoMab anti-mouse ICOSL (CD275) rat IgG2a , ,000 BE0028 HK5.3 InVivoMab anti-mouse ICOSL (CD275) rat IgG2a , ,000 3 ご注文ごとに別途取扱手数料 (2 万円 税別 ) を申し受けます
4 BE0029 GR-20 InVivoMab anti-mouse IFNγR (CD119) rat IgG2a 1 15,000 22,000 BE0029 GR-20 InVivoMab anti-mouse IFNγR (CD119) rat IgG2a 5 55,000 77,000 BE0029 GR-20 InVivoMab anti-mouse IFNγR (CD119) rat IgG2a , ,000 BE0029 GR-20 InVivoMab anti-mouse IFNγR (CD119) rat IgG2a , ,000 BE0029 GR-20 InVivoMab anti-mouse IFNγR (CD119) rat IgG2a , ,000 BE0031 OX-86 InVivoMab anti-mouse OX40 (CD134) rat IgG1 1 15,000 22,000 BE0031 OX-86 InVivoMab anti-mouse OX40 (CD134) rat IgG1 5 55,000 77,000 BE0031 OX-86 InVivoMab anti-mouse OX40 (CD134) rat IgG , ,000 BE0031 OX-86 InVivoMab anti-mouse OX40 (CD134) rat IgG , ,000 BE0031 OX-86 InVivoMab anti-mouse OX40 (CD134) rat IgG , ,000 BE0032 UC10-4F10-11 InVivoMab anti-mouse CTLA-4 (CD152) Armenian hamster IgG 1 15,000 22,000 BE0032 UC10-4F10-11 InVivoMab anti-mouse CTLA-4 (CD152) Armenian hamster IgG 5 55,000 77,000 BE0032 UC10-4F10-11 InVivoMab anti-mouse CTLA-4 (CD152) Armenian hamster IgG , ,000 BE0032 UC10-4F10-11 InVivoMab anti-mouse CTLA-4 (CD152) Armenian hamster IgG , ,000 BE0032 UC10-4F10-11 InVivoMab anti-mouse CTLA-4 (CD152) Armenian hamster IgG , ,000 BE RM134L InVivoMab anti-mouse OX40L (CD134L) rat IgG2b 1 15,000 22,000 BE RM134L InVivoMab anti-mouse OX40L (CD134L) rat IgG2b 5 55,000 77,000 BE RM134L InVivoMab anti-mouse OX40L (CD134L) rat IgG2b , ,000 BE RM134L InVivoMab anti-mouse OX40L (CD134L) rat IgG2b , ,000 BE RM134L InVivoMab anti-mouse OX40L (CD134L) rat IgG2b , ,000 BE J43 InVivoMab anti-mouse PD-1 (CD279) Armenian hamster IgG 1 15,000 22,000 BE J43 InVivoMab anti-mouse PD-1 (CD279) Armenian hamster IgG 5 55,000 77,000 BE J43 InVivoMab anti-mouse PD-1 (CD279) Armenian hamster IgG , ,000 BE J43 InVivoMab anti-mouse PD-1 (CD279) Armenian hamster IgG , ,000 BE J43 InVivoMab anti-mouse PD-1 (CD279) Armenian hamster IgG , ,000 BE0034 DATK32 InVivoMab anti-mouse LPAM-1 (Integrin α4β7) rat IgG2a 1 15,000 22,000 BE0034 DATK32 InVivoMab anti-mouse LPAM-1 (Integrin α4β7) rat IgG2a 5 55,000 77,000 BE0034 DATK32 InVivoMab anti-mouse LPAM-1 (Integrin α4β7) rat IgG2a , ,000 BE0034 DATK32 InVivoMab anti-mouse LPAM-1 (Integrin α4β7) rat IgG2a , ,000 BE0034 DATK32 InVivoMab anti-mouse LPAM-1 (Integrin α4β7) rat IgG2a , ,000 BE0035 MECA-367 InVivoMab anti-mouse MAdCAM-1 rat IgG2a 1 15,000 22,000 BE0035 MECA-367 InVivoMab anti-mouse MAdCAM-1 rat IgG2a 5 55,000 77,000 BE0035 MECA-367 InVivoMab anti-mouse MAdCAM-1 rat IgG2a , ,000 BE0035 MECA-367 InVivoMab anti-mouse MAdCAM-1 rat IgG2a , ,000 BE0035 MECA-367 InVivoMab anti-mouse MAdCAM-1 rat IgG2a , ,000 BE0036 PK136 InVivoMab anti-mouse NK1.1 mouse IgG2a 1 15,000 22,000 BE0036 PK136 InVivoMab anti-mouse NK1.1 mouse IgG2a 5 55,000 77,000 BE0036 PK136 InVivoMab anti-mouse NK1.1 mouse IgG2a , ,000 BE0036 PK136 InVivoMab anti-mouse NK1.1 mouse IgG2a , ,000 BE0036 PK136 InVivoMab anti-mouse NK1.1 mouse IgG2a , ,000 BE0039 IM7 InVivoMab anti-mouse/human CD44 rat IgG2b 1 15,000 22,000 BE0039 IM7 InVivoMab anti-mouse/human CD44 rat IgG2b 5 55,000 77,000 BE0039 IM7 InVivoMab anti-mouse/human CD44 rat IgG2b , ,000 BE0039 IM7 InVivoMab anti-mouse/human CD44 rat IgG2b , ,000 BE0039 IM7 InVivoMab anti-mouse/human CD44 rat IgG2b , ,000 BE0040 JJ319 InVivoMab anti-rat CD28 mouse IgG1 1 15,000 22,000 BE0040 JJ319 InVivoMab anti-rat CD28 mouse IgG1 5 55,000 77,000 BE0040 JJ319 InVivoMab anti-rat CD28 mouse IgG , ,000 BE0040 JJ319 InVivoMab anti-rat CD28 mouse IgG , ,000 BE0040 JJ319 InVivoMab anti-rat CD28 mouse IgG , ,000 BE0042 JES6-5H4 InVivoMab anti-mouse IL-2 rat IgG2b 1 15,000 22,000 BE0042 JES6-5H4 InVivoMab anti-mouse IL-2 rat IgG2b 5 55,000 77,000 BE0042 JES6-5H4 InVivoMab anti-mouse IL-2 rat IgG2b , ,000 BE0042 JES6-5H4 InVivoMab anti-mouse IL-2 rat IgG2b , ,000 BE0042 JES6-5H4 InVivoMab anti-mouse IL-2 rat IgG2b , ,000 BE0043 JES6-1A12 InVivoMab anti-mouse IL-2 rat IgG2a 1 15,000 22,000 BE0043 JES6-1A12 InVivoMab anti-mouse IL-2 rat IgG2a 5 55,000 77,000 BE0043 JES6-1A12 InVivoMab anti-mouse IL-2 rat IgG2a , ,000 BE0043 JES6-1A12 InVivoMab anti-mouse IL-2 rat IgG2a , ,000 BE0043 JES6-1A12 InVivoMab anti-mouse IL-2 rat IgG2a , ,000 BE S4B6-1 InVivoMab anti-mouse IL-2 rat IgG2a 1 15,000 22,000 BE S4B6-1 InVivoMab anti-mouse IL-2 rat IgG2a 5 55,000 77,000 BE S4B6-1 InVivoMab anti-mouse IL-2 rat IgG2a , ,000 4 ご注文ごとに別途取扱手数料 (2 万円 税別 ) を申し受けます
5 BE S4B6-1 InVivoMab anti-mouse IL-2 rat IgG2a , ,000 BE S4B6-1 InVivoMab anti-mouse IL-2 rat IgG2a , ,000 BE B11 InVivoMab anti-mouse IL-4 rat IgG1 1 15,000 22,000 BE B11 InVivoMab anti-mouse IL-4 rat IgG1 5 55,000 77,000 BE B11 InVivoMab anti-mouse IL-4 rat IgG , ,000 BE B11 InVivoMab anti-mouse IL-4 rat IgG , ,000 BE B11 InVivoMab anti-mouse IL-4 rat IgG , ,000 BE0046 MP5-20F3 InVivoMab anti-mouse IL-6 rat IgG1 1 15,000 22,000 BE0046 MP5-20F3 InVivoMab anti-mouse IL-6 rat IgG1 5 55,000 77,000 BE0046 MP5-20F3 InVivoMab anti-mouse IL-6 rat IgG , ,000 BE0046 MP5-20F3 InVivoMab anti-mouse IL-6 rat IgG , ,000 BE0046 MP5-20F3 InVivoMab anti-mouse IL-6 rat IgG , ,000 BE A7 InVivoMab anti-mouse IL-6R rat IgG2b 1 15,000 22,000 BE A7 InVivoMab anti-mouse IL-6R rat IgG2b 5 55,000 77,000 BE A7 InVivoMab anti-mouse IL-6R rat IgG2b , ,000 BE A7 InVivoMab anti-mouse IL-6R rat IgG2b , ,000 BE A7 InVivoMab anti-mouse IL-6R rat IgG2b , ,000 BE0048 M25 InVivoMab anti-mouse/human IL-7 mouse IgG2b 1 15,000 22,000 BE0048 M25 InVivoMab anti-mouse/human IL-7 mouse IgG2b 5 55,000 77,000 BE0048 M25 InVivoMab anti-mouse/human IL-7 mouse IgG2b , ,000 BE0048 M25 InVivoMab anti-mouse/human IL-7 mouse IgG2b , ,000 BE0048 M25 InVivoMab anti-mouse/human IL-7 mouse IgG2b , ,000 BE0049 JES5-2A5 InVivoMab anti-mouse IL-10 rat IgG1 1 15,000 22,000 BE0049 JES5-2A5 InVivoMab anti-mouse IL-10 rat IgG1 5 55,000 77,000 BE0049 JES5-2A5 InVivoMab anti-mouse IL-10 rat IgG , ,000 BE0049 JES5-2A5 InVivoMab anti-mouse IL-10 rat IgG , ,000 BE0049 JES5-2A5 InVivoMab anti-mouse IL-10 rat IgG , ,000 BE0050 1B1.3A InVivoMab anti-mouse IL-10R (CD210) rat IgG1 1 15,000 22,000 BE0050 1B1.3A InVivoMab anti-mouse IL-10R (CD210) rat IgG1 5 55,000 77,000 BE0050 1B1.3A InVivoMab anti-mouse IL-10R (CD210) rat IgG , ,000 BE0050 1B1.3A InVivoMab anti-mouse IL-10R (CD210) rat IgG , ,000 BE0050 1B1.3A InVivoMab anti-mouse IL-10R (CD210) rat IgG , ,000 BE0051 C17.8 InVivoMab anti-mouse IL-12 p40 rat IgG2a 1 15,000 22,000 BE0051 C17.8 InVivoMab anti-mouse IL-12 p40 rat IgG2a 5 55,000 77,000 BE0051 C17.8 InVivoMab anti-mouse IL-12 p40 rat IgG2a , ,000 BE0051 C17.8 InVivoMab anti-mouse IL-12 p40 rat IgG2a , ,000 BE0051 C17.8 InVivoMab anti-mouse IL-12 p40 rat IgG2a , ,000 BE0052 R1-5D9 InVivoMab anti-mouse IL-12 rat IgG2a 1 15,000 22,000 BE0052 R1-5D9 InVivoMab anti-mouse IL-12 rat IgG2a 5 55,000 77,000 BE0052 R1-5D9 InVivoMab anti-mouse IL-12 rat IgG2a , ,000 BE0052 R1-5D9 InVivoMab anti-mouse IL-12 rat IgG2a , ,000 BE0052 R1-5D9 InVivoMab anti-mouse IL-12 rat IgG2a , ,000 BE0054 R4-6A2 InVivoMab anti-mouse IFNγ rat IgG1 1 15,000 22,000 BE0054 R4-6A2 InVivoMab anti-mouse IFNγ rat IgG1 5 55,000 77,000 BE0054 R4-6A2 InVivoMab anti-mouse IFNγ rat IgG , ,000 BE0054 R4-6A2 InVivoMab anti-mouse IFNγ rat IgG , ,000 BE0054 R4-6A2 InVivoMab anti-mouse IFNγ rat IgG , ,000 BE0055 XMG1.2 InVivoMab anti-mouse IFNγ rat IgG1 1 15,000 22,000 BE0055 XMG1.2 InVivoMab anti-mouse IFNγ rat IgG1 5 55,000 77,000 BE0055 XMG1.2 InVivoMab anti-mouse IFNγ rat IgG , ,000 BE0055 XMG1.2 InVivoMab anti-mouse IFNγ rat IgG , ,000 BE0055 XMG1.2 InVivoMab anti-mouse IFNγ rat IgG , ,000 InVivoMab antimouse/human/rat/monkey/hamster/canine/bovine BE0057 1D TGF-β mouse IgG1 1 15,000 22,000 InVivoMab antimouse/human/rat/monkey/hamster/canine/bovine BE0057 1D TGF-β mouse IgG1 5 55,000 77,000 InVivoMab antimouse/human/rat/monkey/hamster/canine/bovine BE0057 1D TGF-β mouse IgG , ,000 InVivoMab antimouse/human/rat/monkey/hamster/canine/bovine BE0057 1D TGF-β mouse IgG , ,000 5 ご注文ごとに別途取扱手数料 (2 万円 税別 ) を申し受けます
6 InVivoMab antimouse/human/rat/monkey/hamster/canine/bovine BE0057 1D TGF-β mouse IgG , ,000 BE0058 XT3.11 InVivoMab anti-mouse TNFα rat IgG1 1 15,000 22,000 BE0058 XT3.11 InVivoMab anti-mouse TNFα rat IgG1 5 55,000 77,000 BE0058 XT3.11 InVivoMab anti-mouse TNFα rat IgG , ,000 BE0058 XT3.11 InVivoMab anti-mouse TNFα rat IgG , ,000 BE0058 XT3.11 InVivoMab anti-mouse TNFα rat IgG , ,000 BE0059 7E.17G9 InVivoMab anti-mouse ICOS rat IgG2b 1 15,000 22,000 BE0059 7E.17G9 InVivoMab anti-mouse ICOS rat IgG2b 5 55,000 77,000 BE0059 7E.17G9 InVivoMab anti-mouse ICOS rat IgG2b , ,000 BE0059 7E.17G9 InVivoMab anti-mouse ICOS rat IgG2b , ,000 BE0059 7E.17G9 InVivoMab anti-mouse ICOS rat IgG2b , ,000 BE0060 DC101 InVivoMab anti-mouse VEGFR-2 rat IgG1 1 15,000 22,000 BE0060 DC101 InVivoMab anti-mouse VEGFR-2 rat IgG1 5 55,000 77,000 BE0060 DC101 InVivoMab anti-mouse VEGFR-2 rat IgG , ,000 BE0060 DC101 InVivoMab anti-mouse VEGFR-2 rat IgG , ,000 BE0060 DC101 InVivoMab anti-mouse VEGFR-2 rat IgG , ,000 BE InVivoMab anti-mouse CD8α rat IgG2b 1 15,000 22,000 BE InVivoMab anti-mouse CD8α rat IgG2b 5 55,000 77,000 BE InVivoMab anti-mouse CD8α rat IgG2b , ,000 BE InVivoMab anti-mouse CD8α rat IgG2b , ,000 BE InVivoMab anti-mouse CD8α rat IgG2b , ,000 BE0062 FIB504 InVivoMab anti-mouse/human Integrin β7 rat IgG2a 1 15,000 22,000 BE0062 FIB504 InVivoMab anti-mouse/human Integrin β7 rat IgG2a 5 55,000 77,000 BE0062 FIB504 InVivoMab anti-mouse/human Integrin β7 rat IgG2a , ,000 BE0062 FIB504 InVivoMab anti-mouse/human Integrin β7 rat IgG2a , ,000 BE0062 FIB504 InVivoMab anti-mouse/human Integrin β7 rat IgG2a , ,000 BE0063 DTA-1 InVivoMab anti-mouse GITR rat IgG2b 1 15,000 22,000 BE0063 DTA-1 InVivoMab anti-mouse GITR rat IgG2b 5 55,000 77,000 BE0063 DTA-1 InVivoMab anti-mouse GITR rat IgG2b , ,000 BE0063 DTA-1 InVivoMab anti-mouse GITR rat IgG2b , ,000 BE0063 DTA-1 InVivoMab anti-mouse GITR rat IgG2b , ,000 BE0065 A7R34 InVivoMab anti-mouse IL-7Rα (CD127) rat IgG2a 1 15,000 22,000 BE0065 A7R34 InVivoMab anti-mouse IL-7Rα (CD127) rat IgG2a 5 55,000 77,000 BE0065 A7R34 InVivoMab anti-mouse IL-7Rα (CD127) rat IgG2a , ,000 BE0065 A7R34 InVivoMab anti-mouse IL-7Rα (CD127) rat IgG2a , ,000 BE0065 A7R34 InVivoMab anti-mouse IL-7Rα (CD127) rat IgG2a , ,000 BE H12 InVivoMab anti-mouse Thy1.2 (CD90.2) rat IgG2b 1 15,000 22,000 BE H12 InVivoMab anti-mouse Thy1.2 (CD90.2) rat IgG2b 5 55,000 77,000 BE H12 InVivoMab anti-mouse Thy1.2 (CD90.2) rat IgG2b , ,000 BE H12 InVivoMab anti-mouse Thy1.2 (CD90.2) rat IgG2b , ,000 BE H12 InVivoMab anti-mouse Thy1.2 (CD90.2) rat IgG2b , ,000 BE0067 RA3.3A1/6.1 InVivoMab anti-mouse B220 rat IgM 1 15,000 22,000 BE0067 RA3.3A1/6.1 InVivoMab anti-mouse B220 rat IgM 5 55,000 77,000 BE0067 RA3.3A1/6.1 InVivoMab anti-mouse B220 rat IgM , ,000 BE0067 RA3.3A1/6.1 InVivoMab anti-mouse B220 rat IgM , ,000 BE0067 RA3.3A1/6.1 InVivoMab anti-mouse B220 rat IgM , ,000 InVivoMab anti-mouse MHC Class II (I-Ak, I-Ar, I-Af, I- BE As,I-Ag7) mouse IgG2a 1 15,000 22,000 InVivoMab anti-mouse MHC Class II (I-Ak, I-Ar, I-Af, I- BE As,I-Ag7) mouse IgG2a 5 55,000 77,000 InVivoMab anti-mouse MHC Class II (I-Ak, I-Ar, I-Af, I- BE As,I-Ag7) mouse IgG2a , ,000 InVivoMab anti-mouse MHC Class II (I-Ak, I-Ar, I-Af, I- BE As,I-Ag7) mouse IgG2a , ,000 InVivoMab anti-mouse MHC Class II (I-Ak, I-Ar, I-Af, I- BE As,I-Ag7) mouse IgG2a , ,000 BE0069 1B2 InVivoMab anti-mouse 2C TCR mouse IgG1 1 15,000 22,000 BE0069 1B2 InVivoMab anti-mouse 2C TCR mouse IgG1 5 55,000 77,000 BE0069 1B2 InVivoMab anti-mouse 2C TCR mouse IgG , ,000 BE0069 1B2 InVivoMab anti-mouse 2C TCR mouse IgG , ,000 BE0069 1B2 InVivoMab anti-mouse 2C TCR mouse IgG , ,000 BE0070 UC7-13D5 InVivoMab anti-mouse TCR γ/δ Armenian hamster IgG 1 15,000 22,000 6 ご注文ごとに別途取扱手数料 (2 万円 税別 ) を申し受けます
7 BE0070 UC7-13D5 InVivoMab anti-mouse TCR γ/δ Armenian hamster IgG 5 55,000 77,000 BE0070 UC7-13D5 InVivoMab anti-mouse TCR γ/δ Armenian hamster IgG , ,000 BE0070 UC7-13D5 InVivoMab anti-mouse TCR γ/δ Armenian hamster IgG , ,000 BE0070 UC7-13D5 InVivoMab anti-mouse TCR γ/δ Armenian hamster IgG , ,000 BE0071 PS/2 InVivoMab anti-mouse/human VLA-4 (CD49d) rat IgG2b 1 15,000 22,000 BE0071 PS/2 InVivoMab anti-mouse/human VLA-4 (CD49d) rat IgG2b 5 55,000 77,000 BE0071 PS/2 InVivoMab anti-mouse/human VLA-4 (CD49d) rat IgG2b , ,000 BE0071 PS/2 InVivoMab anti-mouse/human VLA-4 (CD49d) rat IgG2b , ,000 BE0071 PS/2 InVivoMab anti-mouse/human VLA-4 (CD49d) rat IgG2b , ,000 InVivoMab anti-mouse T15 VH and T15 VL regions of BE0072 AB1-2 (HB-33) IgM mouse IgG1 1 15,000 22,000 InVivoMab anti-mouse T15 VH and T15 VL regions of BE0072 AB1-2 (HB-33) IgM mouse IgG1 5 55,000 77,000 InVivoMab anti-mouse T15 VH and T15 VL regions of BE0072 AB1-2 (HB-33) IgM mouse IgG , ,000 InVivoMab anti-mouse T15 VH and T15 VL regions of BE0072 AB1-2 (HB-33) IgM mouse IgG , ,000 InVivoMab anti-mouse T15 VH and T15 VL regions of BE0072 AB1-2 (HB-33) IgM mouse IgG , ,000 BE0075 RB6-8C5 InVivoMab anti-mouse Ly6G/Ly6C (Gr-1) rat IgG2b 1 15,000 22,000 BE0075 RB6-8C5 InVivoMab anti-mouse Ly6G/Ly6C (Gr-1) rat IgG2b 5 55,000 77,000 BE0075 RB6-8C5 InVivoMab anti-mouse Ly6G/Ly6C (Gr-1) rat IgG2b , ,000 BE0075 RB6-8C5 InVivoMab anti-mouse Ly6G/Ly6C (Gr-1) rat IgG2b , ,000 BE0075 RB6-8C5 InVivoMab anti-mouse Ly6G/Ly6C (Gr-1) rat IgG2b , ,000 BE A8 InVivoMab anti-mouse Ly6G rat IgG2a 1 15,000 22,000 BE A8 InVivoMab anti-mouse Ly6G rat IgG2a 5 55,000 77,000 BE A8 InVivoMab anti-mouse Ly6G rat IgG2a , ,000 BE A8 InVivoMab anti-mouse Ly6G rat IgG2a , ,000 BE A8 InVivoMab anti-mouse Ly6G rat IgG2a , ,000 BE0076 M5/ InVivoMab anti-mouse Thy1 (CD90) rat IgG2a 1 15,000 22,000 BE0076 M5/ InVivoMab anti-mouse Thy1 (CD90) rat IgG2a 5 55,000 77,000 BE0076 M5/ InVivoMab anti-mouse Thy1 (CD90) rat IgG2a , ,000 BE0076 M5/ InVivoMab anti-mouse Thy1 (CD90) rat IgG2a , ,000 BE0076 M5/ InVivoMab anti-mouse Thy1 (CD90) rat IgG2a , ,000 BE0077 M1/ InVivoMab anti-mouse MHC Class I (H-2) rat IgG2a 1 15,000 22,000 BE0077 M1/ InVivoMab anti-mouse MHC Class I (H-2) rat IgG2a 5 55,000 77,000 BE0077 M1/ InVivoMab anti-mouse MHC Class I (H-2) rat IgG2a , ,000 BE0077 M1/ InVivoMab anti-mouse MHC Class I (H-2) rat IgG2a , ,000 BE0077 M1/ InVivoMab anti-mouse MHC Class I (H-2) rat IgG2a , ,000 InVivoMab anti-human MHC Class I (HLA-A, HLA-B, BE0079 W6/32 HLA-C) mouse IgG2a 1 15,000 22,000 InVivoMab anti-human MHC Class I (HLA-A, HLA-B, BE0079 W6/32 HLA-C) mouse IgG2a 5 55,000 77,000 InVivoMab anti-human MHC Class I (HLA-A, HLA-B, BE0079 W6/32 HLA-C) mouse IgG2a , ,000 InVivoMab anti-human MHC Class I (HLA-A, HLA-B, BE0079 W6/32 HLA-C) mouse IgG2a , ,000 InVivoMab anti-human MHC Class I (HLA-A, HLA-B, BE0079 W6/32 HLA-C) mouse IgG2a , ,000 BE0083 MOPC-21 InVivoMab mouse IgG1 isotype control mouse IgG1 1 15,000 22,000 BE0083 MOPC-21 InVivoMab mouse IgG1 isotype control mouse IgG1 5 55,000 77,000 BE0083 MOPC-21 InVivoMab mouse IgG1 isotype control mouse IgG , ,000 BE0083 MOPC-21 InVivoMab mouse IgG1 isotype control mouse IgG , ,000 BE0083 MOPC-21 InVivoMab mouse IgG1 isotype control mouse IgG , ,000 BE0085 C InVivoMab mouse IgG2a isotype control mouse IgG2a 1 15,000 22,000 BE0085 C InVivoMab mouse IgG2a isotype control mouse IgG2a 5 55,000 77,000 BE0085 C InVivoMab mouse IgG2a isotype control mouse IgG2a , ,000 BE0085 C InVivoMab mouse IgG2a isotype control mouse IgG2a , ,000 BE0085 C InVivoMab mouse IgG2a isotype control mouse IgG2a , ,000 BE0086 MPC-11 InVivoMab mouse IgG2b isotype control mouse IgG2b 1 15,000 22,000 BE0086 MPC-11 InVivoMab mouse IgG2b isotype control mouse IgG2b 5 55,000 77,000 BE0086 MPC-11 InVivoMab mouse IgG2b isotype control mouse IgG2b , ,000 BE0086 MPC-11 InVivoMab mouse IgG2b isotype control mouse IgG2b , ,000 BE0086 MPC-11 InVivoMab mouse IgG2b isotype control mouse IgG2b , ,000 7 ご注文ごとに別途取扱手数料 (2 万円 税別 ) を申し受けます
8 BE0087 Polyclonal Syrian InVivoMab polyclonal Syrian hamster IgG Syrian hamster IgG 1 15,000 22,000 BE0087 Polyclonal Syrian InVivoMab polyclonal Syrian hamster IgG Syrian hamster IgG 5 55,000 77,000 BE0087 Polyclonal Syrian InVivoMab polyclonal Syrian hamster IgG Syrian hamster IgG , ,000 BE0087 Polyclonal Syrian InVivoMab polyclonal Syrian hamster IgG Syrian hamster IgG , ,000 BE0087 Polyclonal Syrian InVivoMab polyclonal Syrian hamster IgG Syrian hamster IgG , ,000 BE0088 HRPN InVivoMab rat IgG1 isotype control (anti-hrp) rat IgG1 1 15,000 22,000 BE0088 HRPN InVivoMab rat IgG1 isotype control (anti-hrp) rat IgG1 5 55,000 77,000 BE0088 HRPN InVivoMab rat IgG1 isotype control (anti-hrp) rat IgG , ,000 BE0088 HRPN InVivoMab rat IgG1 isotype control (anti-hrp) rat IgG , ,000 BE0088 HRPN InVivoMab rat IgG1 isotype control (anti-hrp) rat IgG , ,000 BE0089 2A3 InVivoMab rat IgG2a isotype control rat IgG2a 1 15,000 22,000 BE0089 2A3 InVivoMab rat IgG2a isotype control rat IgG2a 5 55,000 77,000 BE0089 2A3 InVivoMab rat IgG2a isotype control rat IgG2a , ,000 BE0089 2A3 InVivoMab rat IgG2a isotype control rat IgG2a , ,000 BE0089 2A3 InVivoMab rat IgG2a isotype control rat IgG2a , ,000 BE0090 LTF-2 InVivoMab rat IgG2b isotype control rat IgG2b 1 15,000 22,000 BE0090 LTF-2 InVivoMab rat IgG2b isotype control rat IgG2b 5 55,000 77,000 BE0090 LTF-2 InVivoMab rat IgG2b isotype control rat IgG2b , ,000 BE0090 LTF-2 InVivoMab rat IgG2b isotype control rat IgG2b , ,000 BE0090 LTF-2 InVivoMab rat IgG2b isotype control rat IgG2b , ,000 BE0091 Polyclonal Armenian InVivoMab polyclonal Armenian hamster IgG Armenian hamster IgG 1 15,000 22,000 BE0091 Polyclonal Armenian InVivoMab polyclonal Armenian hamster IgG Armenian hamster IgG 5 55,000 77,000 BE0091 Polyclonal Armenian InVivoMab polyclonal Armenian hamster IgG Armenian hamster IgG , ,000 BE0091 Polyclonal Armenian InVivoMab polyclonal Armenian hamster IgG Armenian hamster IgG , ,000 BE0091 Polyclonal Armenian InVivoMab polyclonal Armenian hamster IgG Armenian hamster IgG , ,000 hamster IgG f(ab )2 BE0091-FAB Fragments InVivoMab Armenian hamster IgG f(ab )2 fragments Polyclonal 5 78, ,000 hamster IgG f(ab )2 BE0091-FAB Fragments InVivoMab Armenian hamster IgG f(ab )2 fragments Polyclonal , ,000 hamster IgG f(ab )2 BE0091-FAB Fragments InVivoMab Armenian hamster IgG f(ab )2 fragments Polyclonal , ,000 hamster IgG f(ab )2 BE0091-FAB Fragments InVivoMab Armenian hamster IgG f(ab )2 fragments Polyclonal , ,000 BE0092 Polyclonal InVivoMab polyclonal human IgG human IgG 1 15,000 22,000 BE0092 Polyclonal InVivoMab polyclonal human IgG human IgG 5 55,000 77,000 BE0092 Polyclonal InVivoMab polyclonal human IgG human IgG , ,000 BE0092 Polyclonal InVivoMab polyclonal human IgG human IgG , ,000 BE0092 Polyclonal InVivoMab polyclonal human IgG human IgG , ,000 BE0093 Polyclonal InVivoMab polyclonal mouse IgG mouse IgG 1 15,000 22,000 BE0093 Polyclonal InVivoMab polyclonal mouse IgG mouse IgG 5 55,000 77,000 BE0093 Polyclonal InVivoMab polyclonal mouse IgG mouse IgG , ,000 BE0093 Polyclonal InVivoMab polyclonal mouse IgG mouse IgG , ,000 BE0093 Polyclonal InVivoMab polyclonal mouse IgG mouse IgG , ,000 BE0094 Polyclonal InVivoMab polyclonal rat IgG rat IgG 1 15,000 22,000 BE0094 Polyclonal InVivoMab polyclonal rat IgG rat IgG 5 55,000 77,000 BE0094 Polyclonal InVivoMab polyclonal rat IgG rat IgG , ,000 BE0094 Polyclonal InVivoMab polyclonal rat IgG rat IgG , ,000 BE0094 Polyclonal InVivoMab polyclonal rat IgG rat IgG , ,000 BE0096 human Fc-G1 InVivoMab recombinant human IgG1 Fc Rabbit IgG 1 15,000 22,000 BE0096 human Fc-G1 InVivoMab recombinant human IgG1 Fc Rabbit IgG 5 55,000 77,000 BE0096 human Fc-G1 InVivoMab recombinant human IgG1 Fc Rabbit IgG , ,000 BE0096 human Fc-G1 InVivoMab recombinant human IgG1 Fc Rabbit IgG , ,000 BE0096 human Fc-G1 InVivoMab recombinant human IgG1 Fc Rabbit IgG , ,000 BE0097 mouse Fc G2a InVivoMab recombinant mouse IgG2a Fc Rabbit IgG 1 15,000 22,000 BE0097 mouse Fc G2a InVivoMab recombinant mouse IgG2a Fc Rabbit IgG 5 55,000 77,000 BE0097 mouse Fc G2a InVivoMab recombinant mouse IgG2a Fc Rabbit IgG , ,000 BE0097 mouse Fc G2a InVivoMab recombinant mouse IgG2a Fc Rabbit IgG , ,000 BE0097 mouse Fc G2a InVivoMab recombinant mouse IgG2a Fc Rabbit IgG , ,000 BE0098 Flt-3L-Ig (hum./hum.) InVivoMab recombinant Flt-3L-Ig (hum./hum.) Rabbit IgG , ,000 BE0098 Flt-3L-Ig (hum./hum.) InVivoMab recombinant Flt-3L-Ig (hum./hum.) Rabbit IgG , ,000 BE0098 Flt-3L-Ig (hum./hum.) InVivoMab recombinant Flt-3L-Ig (hum./hum.) Rabbit IgG ,000 1,323,000 BE0099 CTLA-4-Ig (hum./hum.) InVivoMab recombinant CTLA-4-Ig (hum./hum.) Rabbit IgG 5 55,000 84,000 BE0099 CTLA-4-Ig (hum./hum.) InVivoMab recombinant CTLA-4-Ig (hum./hum.) Rabbit IgG , ,000 BE0099 CTLA-4-Ig (hum./hum.) InVivoMab recombinant CTLA-4-Ig (hum./hum.) Rabbit IgG , ,000 8 ご注文ごとに別途取扱手数料 (2 万円 税別 ) を申し受けます
9 BE0099 CTLA-4-Ig (hum./hum.) InVivoMab recombinant CTLA-4-Ig (hum./hum.) Rabbit IgG , ,000 BE0100 4B10 InVivoMab anti-mouse/human T-bet mouse IgG1 1 15,000 22,000 BE0100 4B10 InVivoMab anti-mouse/human T-bet mouse IgG1 5 55,000 77,000 BE0100 4B10 InVivoMab anti-mouse/human T-bet mouse IgG , ,000 BE0100 4B10 InVivoMab anti-mouse/human T-bet mouse IgG , ,000 BE0100 4B10 InVivoMab anti-mouse/human T-bet mouse IgG , ,000 BE F.9G2 InVivoMab anti-mouse PD-L1 (B7-H1) rat IgG2b 1 15,000 22,000 BE F.9G2 InVivoMab anti-mouse PD-L1 (B7-H1) rat IgG2b 5 55,000 84,000 BE F.9G2 InVivoMab anti-mouse PD-L1 (B7-H1) rat IgG2b , ,000 BE F.9G2 InVivoMab anti-mouse PD-L1 (B7-H1) rat IgG2b , ,000 BE F.9G2 InVivoMab anti-mouse PD-L1 (B7-H1) rat IgG2b , ,000 BE0102 H (HB-218) InVivoMab anti-mouse TCRβ Armenian hamster IgG 1 15,000 22,000 BE0102 H (HB-218) InVivoMab anti-mouse TCRβ Armenian hamster IgG 5 55,000 77,000 BE0102 H (HB-218) InVivoMab anti-mouse TCRβ Armenian hamster IgG , ,000 BE0102 H (HB-218) InVivoMab anti-mouse TCRβ Armenian hamster IgG , ,000 BE0102 H (HB-218) InVivoMab anti-mouse TCRβ Armenian hamster IgG , ,000 BE0104 SF (HB-159) InVivoMab anti-mouse MHC Class I (H-2Kd) mouse IgG2a 1 15,000 22,000 BE0104 SF (HB-159) InVivoMab anti-mouse MHC Class I (H-2Kd) mouse IgG2a 5 55,000 77,000 BE0104 SF (HB-159) InVivoMab anti-mouse MHC Class I (H-2Kd) mouse IgG2a , ,000 BE0104 SF (HB-159) InVivoMab anti-mouse MHC Class I (H-2Kd) mouse IgG2a , ,000 BE0104 SF (HB-159) InVivoMab anti-mouse MHC Class I (H-2Kd) mouse IgG2a , ,000 BE0106 VL-4 InVivoMab anti-lcmv nucleoprotein rat IgG2a 1 15,000 22,000 BE0106 VL-4 InVivoMab anti-lcmv nucleoprotein rat IgG2a 5 55,000 77,000 BE0106 VL-4 InVivoMab anti-lcmv nucleoprotein rat IgG2a , ,000 BE0106 VL-4 InVivoMab anti-lcmv nucleoprotein rat IgG2a , ,000 BE0106 VL-4 InVivoMab anti-lcmv nucleoprotein rat IgG2a , ,000 BE0108 M5/114 InVivoMab anti-mouse MHC Class II (I-A/I-E) rat IgG2b 1 15,000 22,000 BE0108 M5/114 InVivoMab anti-mouse MHC Class II (I-A/I-E) rat IgG2b 5 55,000 77,000 BE0108 M5/114 InVivoMab anti-mouse MHC Class II (I-A/I-E) rat IgG2b , ,000 BE0108 M5/114 InVivoMab anti-mouse MHC Class II (I-A/I-E) rat IgG2b , ,000 BE0108 M5/114 InVivoMab anti-mouse MHC Class II (I-A/I-E) rat IgG2b , ,000 BE0110 TKS-1 InVivoMab anti-mouse 4-1BBL (CD137L) rat IgG2a 1 15,000 22,000 BE0110 TKS-1 InVivoMab anti-mouse 4-1BBL (CD137L) rat IgG2a 5 55,000 77,000 BE0110 TKS-1 InVivoMab anti-mouse 4-1BBL (CD137L) rat IgG2a , ,000 BE0110 TKS-1 InVivoMab anti-mouse 4-1BBL (CD137L) rat IgG2a , ,000 BE0110 TKS-1 InVivoMab anti-mouse 4-1BBL (CD137L) rat IgG2a , ,000 BE0111 HMG2D InVivoMab anti-mouse NKG2D Armenian hamster IgG 1 15,000 22,000 BE0111 HMG2D InVivoMab anti-mouse NKG2D Armenian hamster IgG 5 55,000 77,000 BE0111 HMG2D InVivoMab anti-mouse NKG2D Armenian hamster IgG , ,000 BE0111 HMG2D InVivoMab anti-mouse NKG2D Armenian hamster IgG , ,000 BE0111 HMG2D InVivoMab anti-mouse NKG2D Armenian hamster IgG , ,000 BE0112 TY25 InVivoMab anti-mouse PD-L2 (B7-DC) rat IgG2a 1 15,000 22,000 BE0112 TY25 InVivoMab anti-mouse PD-L2 (B7-DC) rat IgG2a 5 55,000 77,000 BE0112 TY25 InVivoMab anti-mouse PD-L2 (B7-DC) rat IgG2a , ,000 BE0112 TY25 InVivoMab anti-mouse PD-L2 (B7-DC) rat IgG2a , ,000 BE0112 TY25 InVivoMab anti-mouse PD-L2 (B7-DC) rat IgG2a , ,000 BE0113 RMT1-10 InVivoMab anti-mouse TIM-1 (CD365) rat IgG2a 1 15,000 22,000 BE0113 RMT1-10 InVivoMab anti-mouse TIM-1 (CD365) rat IgG2a 5 55,000 77,000 BE0113 RMT1-10 InVivoMab anti-mouse TIM-1 (CD365) rat IgG2a , ,000 BE0113 RMT1-10 InVivoMab anti-mouse TIM-1 (CD365) rat IgG2a , ,000 BE0113 RMT1-10 InVivoMab anti-mouse TIM-1 (CD365) rat IgG2a , ,000 BE0114 RMT2-29 InVivoMab anti-mouse TIM-2 rat IgM 1 15,000 22,000 BE0114 RMT2-29 InVivoMab anti-mouse TIM-2 rat IgM 5 55,000 77,000 BE0114 RMT2-29 InVivoMab anti-mouse TIM-2 rat IgM , ,000 BE0114 RMT2-29 InVivoMab anti-mouse TIM-2 rat IgM , ,000 BE0114 RMT2-29 InVivoMab anti-mouse TIM-2 rat IgM , ,000 BE0115 RMT3-23 InVivoMab anti-mouse TIM-3 (CD366) rat IgG2a 1 15,000 22,000 BE0115 RMT3-23 InVivoMab anti-mouse TIM-3 (CD366) rat IgG2a 5 55,000 77,000 BE0115 RMT3-23 InVivoMab anti-mouse TIM-3 (CD366) rat IgG2a , ,000 BE0115 RMT3-23 InVivoMab anti-mouse TIM-3 (CD366) rat IgG2a , ,000 BE0115 RMT3-23 InVivoMab anti-mouse TIM-3 (CD366) rat IgG2a , ,000 BE0117 YTS169.4 InVivoMab anti-mouse CD8α rat IgG2b 1 15,000 22,000 BE0117 YTS169.4 InVivoMab anti-mouse CD8α rat IgG2b 5 55,000 77,000 9 ご注文ごとに別途取扱手数料 (2 万円 税別 ) を申し受けます
10 BE0117 YTS169.4 InVivoMab anti-mouse CD8α rat IgG2b , ,000 BE0117 YTS169.4 InVivoMab anti-mouse CD8α rat IgG2b , ,000 BE0117 YTS169.4 InVivoMab anti-mouse CD8α rat IgG2b , ,000 BE (HB-129) InVivoMab anti-mouse CD8 (Lyt 2.1) mouse IgG2a 1 15,000 22,000 BE (HB-129) InVivoMab anti-mouse CD8 (Lyt 2.1) mouse IgG2a 5 55,000 77,000 BE (HB-129) InVivoMab anti-mouse CD8 (Lyt 2.1) mouse IgG2a , ,000 BE (HB-129) InVivoMab anti-mouse CD8 (Lyt 2.1) mouse IgG2a , ,000 BE (HB-129) InVivoMab anti-mouse CD8 (Lyt 2.1) mouse IgG2a , ,000 BE0119 YTS 191 InVivoMab anti-mouse CD4 rat IgG2b 1 15,000 22,000 BE0119 YTS 191 InVivoMab anti-mouse CD4 rat IgG2b 5 55,000 77,000 BE0119 YTS 191 InVivoMab anti-mouse CD4 rat IgG2b , ,000 BE0119 YTS 191 InVivoMab anti-mouse CD4 rat IgG2b , ,000 BE0119 YTS 191 InVivoMab anti-mouse CD4 rat IgG2b , ,000 BE (HB139) InVivoMab anti-swine MHC Class I (SLAd) mouse IgG2b 1 15,000 22,000 BE (HB139) InVivoMab anti-swine MHC Class I (SLAd) mouse IgG2b 5 55,000 77,000 BE (HB139) InVivoMab anti-swine MHC Class I (SLAd) mouse IgG2b , ,000 BE (HB139) InVivoMab anti-swine MHC Class I (SLAd) mouse IgG2b , ,000 BE (HB139) InVivoMab anti-swine MHC Class I (SLAd) mouse IgG2b , ,000 BE0121 AF InVivoMab anti-mouse MHC Class I (H-2Kb) mouse IgG2a 1 15,000 22,000 BE0121 AF InVivoMab anti-mouse MHC Class I (H-2Kb) mouse IgG2a 5 55,000 77,000 BE0121 AF InVivoMab anti-mouse MHC Class I (H-2Kb) mouse IgG2a , ,000 BE0121 AF InVivoMab anti-mouse MHC Class I (H-2Kb) mouse IgG2a , ,000 BE0121 AF InVivoMab anti-mouse MHC Class I (H-2Kb) mouse IgG2a , ,000 InVivoMab anti-rat Kappa Immunoglobulin Light BE0122 MAR 18.5 Chain mouse IgG2a 1 15,000 22,000 InVivoMab anti-rat Kappa Immunoglobulin Light BE0122 MAR 18.5 Chain mouse IgG2a 5 55,000 77,000 InVivoMab anti-rat Kappa Immunoglobulin Light BE0122 MAR 18.5 Chain mouse IgG2a , ,000 InVivoMab anti-rat Kappa Immunoglobulin Light BE0122 MAR 18.5 Chain mouse IgG2a , ,000 InVivoMab anti-rat Kappa Immunoglobulin Light BE0122 MAR 18.5 Chain mouse IgG2a , ,000 BE0123 Mab35 (TIB-175) InVivoMab anti-human/rat/fish AChR rat IgG1 1 15,000 22,000 BE0123 Mab35 (TIB-175) InVivoMab anti-human/rat/fish AChR rat IgG1 5 55,000 77,000 BE0123 Mab35 (TIB-175) InVivoMab anti-human/rat/fish AChR rat IgG , ,000 BE0123 Mab35 (TIB-175) InVivoMab anti-human/rat/fish AChR rat IgG , ,000 BE0123 Mab35 (TIB-175) InVivoMab anti-human/rat/fish AChR rat IgG , ,000 BE0124 MJ18 InVivoMab anti-mouse B7-H3 rat IgG1 1 15,000 22,000 BE0124 MJ18 InVivoMab anti-mouse B7-H3 rat IgG1 5 55,000 77,000 BE0124 MJ18 InVivoMab anti-mouse B7-H3 rat IgG , ,000 BE0124 MJ18 InVivoMab anti-mouse B7-H3 rat IgG , ,000 BE0124 MJ18 InVivoMab anti-mouse B7-H3 rat IgG , ,000 BE0125 HMJ2-1 InVivoMab anti-mouse Jagged2 Armenian hamster IgG 1 15,000 22,000 BE0125 HMJ2-1 InVivoMab anti-mouse Jagged2 Armenian hamster IgG 5 55,000 77,000 BE0125 HMJ2-1 InVivoMab anti-mouse Jagged2 Armenian hamster IgG , ,000 BE0125 HMJ2-1 InVivoMab anti-mouse Jagged2 Armenian hamster IgG , ,000 BE0125 HMJ2-1 InVivoMab anti-mouse Jagged2 Armenian hamster IgG , ,000 BE0127 HMD4-2 InVivoMab anti-mouse Delta-like protein 4 (DLL4) Armenian hamster IgG 1 15,000 22,000 BE0127 HMD4-2 InVivoMab anti-mouse Delta-like protein 4 (DLL4) Armenian hamster IgG 5 55,000 77,000 BE0127 HMD4-2 InVivoMab anti-mouse Delta-like protein 4 (DLL4) Armenian hamster IgG , ,000 BE0127 HMD4-2 InVivoMab anti-mouse Delta-like protein 4 (DLL4) Armenian hamster IgG , ,000 BE0127 HMD4-2 InVivoMab anti-mouse Delta-like protein 4 (DLL4) Armenian hamster IgG , ,000 BE0129 HMN4-14 InVivoMab anti-mouse Notch4 Armenian hamster IgG 1 15,000 22,000 BE0129 HMN4-14 InVivoMab anti-mouse Notch4 Armenian hamster IgG 5 55,000 77,000 BE0129 HMN4-14 InVivoMab anti-mouse Notch4 Armenian hamster IgG , ,000 BE0129 HMN4-14 InVivoMab anti-mouse Notch4 Armenian hamster IgG , ,000 BE0129 HMN4-14 InVivoMab anti-mouse Notch4 Armenian hamster IgG , ,000 BE0131 9H10 InVivoMab anti-mouse CTLA-4 (CD152) Syrian hamster IgG2 1 15,000 22,000 BE0131 9H10 InVivoMab anti-mouse CTLA-4 (CD152) Syrian hamster IgG2 5 55,000 84,000 BE0131 9H10 InVivoMab anti-mouse CTLA-4 (CD152) Syrian hamster IgG , ,000 BE0131 9H10 InVivoMab anti-mouse CTLA-4 (CD152) Syrian hamster IgG , ,000 BE0131 9H10 InVivoMab anti-mouse CTLA-4 (CD152) Syrian hamster IgG , ,000 BE0132 6A6 InVivoMab anti-mouse BTLA (CD272) Armenian hamster IgG 1 15,000 22, ご注文ごとに別途取扱手数料 (2 万円 税別 ) を申し受けます
11 BE0132 6A6 InVivoMab anti-mouse BTLA (CD272) Armenian hamster IgG 5 55,000 77,000 BE0132 6A6 InVivoMab anti-mouse BTLA (CD272) Armenian hamster IgG , ,000 BE0132 6A6 InVivoMab anti-mouse BTLA (CD272) Armenian hamster IgG , ,000 BE0132 6A6 InVivoMab anti-mouse BTLA (CD272) Armenian hamster IgG , ,000 BE0133 C7 InVivoMab anti-human/bovine LDLR mouse IgG2b 1 15,000 22,000 BE0133 C7 InVivoMab anti-human/bovine LDLR mouse IgG2b 5 55,000 77,000 BE0133 C7 InVivoMab anti-human/bovine LDLR mouse IgG2b , ,000 BE0133 C7 InVivoMab anti-human/bovine LDLR mouse IgG2b , ,000 BE0133 C7 InVivoMab anti-human/bovine LDLR mouse IgG2b , ,000 BE0134 1G10 InVivoMab anti-mouse B7-1 (CD80) rat IgG2a 1 15,000 22,000 BE0134 1G10 InVivoMab anti-mouse B7-1 (CD80) rat IgG2a 5 55,000 77,000 BE0134 1G10 InVivoMab anti-mouse B7-1 (CD80) rat IgG2a , ,000 BE0134 1G10 InVivoMab anti-mouse B7-1 (CD80) rat IgG2a , ,000 BE0134 1G10 InVivoMab anti-mouse B7-1 (CD80) rat IgG2a , ,000 BE0136 CL2 InVivoMab anti-human E-Selectin mouse IgG2a 1 15,000 22,000 BE0136 CL2 InVivoMab anti-human E-Selectin mouse IgG2a 5 55,000 77,000 BE0136 CL2 InVivoMab anti-human E-Selectin mouse IgG2a , ,000 BE0136 CL2 InVivoMab anti-human E-Selectin mouse IgG2a , ,000 BE0136 CL2 InVivoMab anti-human E-Selectin mouse IgG2a , ,000 BE0139 Y InVivoMab anti-mouse/human/rat v-h-ras rat IgG2a 1 15,000 22,000 BE0139 Y InVivoMab anti-mouse/human/rat v-h-ras rat IgG2a 5 55,000 77,000 BE0139 Y InVivoMab anti-mouse/human/rat v-h-ras rat IgG2a , ,000 BE0139 Y InVivoMab anti-mouse/human/rat v-h-ras rat IgG2a , ,000 BE0139 Y InVivoMab anti-mouse/human/rat v-h-ras rat IgG2a , ,000 BE0140 KL277 InVivoMab anti-mouse MHC Class II (β chain) hamster/mouse IgG 1 15,000 22,000 BE0140 KL277 InVivoMab anti-mouse MHC Class II (β chain) hamster/mouse IgG 5 55,000 77,000 BE0140 KL277 InVivoMab anti-mouse MHC Class II (β chain) hamster/mouse IgG , ,000 BE0140 KL277 InVivoMab anti-mouse MHC Class II (β chain) hamster/mouse IgG , ,000 BE0140 KL277 InVivoMab anti-mouse MHC Class II (β chain) hamster/mouse IgG , ,000 BE InVivoMab anti-mouse 3-83 Ig rat IgG kappa 1 15,000 22,000 BE InVivoMab anti-mouse 3-83 Ig rat IgG kappa 5 55,000 77,000 BE InVivoMab anti-mouse 3-83 Ig rat IgG kappa , ,000 BE InVivoMab anti-mouse 3-83 Ig rat IgG kappa , ,000 BE InVivoMab anti-mouse 3-83 Ig rat IgG kappa , ,000 BE0143 4C9 InVivoMab anti-rat β-2-microglobulin mouse IgG1 1 15,000 22,000 BE0143 4C9 InVivoMab anti-rat β-2-microglobulin mouse IgG1 5 55,000 77,000 BE0143 4C9 InVivoMab anti-rat β-2-microglobulin mouse IgG , ,000 BE0143 4C9 InVivoMab anti-rat β-2-microglobulin mouse IgG , ,000 BE0143 4C9 InVivoMab anti-rat β-2-microglobulin mouse IgG , ,000 BE0144 2G3 InVivoMab anti-rat FcRn heavy chain heterodimers mouse IgG1 1 15,000 22,000 BE0144 2G3 InVivoMab anti-rat FcRn heavy chain heterodimers mouse IgG1 5 55,000 77,000 BE0144 2G3 InVivoMab anti-rat FcRn heavy chain heterodimers mouse IgG , ,000 BE0144 2G3 InVivoMab anti-rat FcRn heavy chain heterodimers mouse IgG , ,000 BE0144 2G3 InVivoMab anti-rat FcRn heavy chain heterodimers mouse IgG , ,000 BE0146 RMP1-14 InVivoMab anti-mouse PD-1 (CD279) rat IgG2a 1 15,000 22,000 BE0146 RMP1-14 InVivoMab anti-mouse PD-1 (CD279) rat IgG2a 5 55,000 84,000 BE0146 RMP1-14 InVivoMab anti-mouse PD-1 (CD279) rat IgG2a , ,000 BE0146 RMP1-14 InVivoMab anti-mouse PD-1 (CD279) rat IgG2a , ,000 BE0146 RMP1-14 InVivoMab anti-mouse PD-1 (CD279) rat IgG2a , ,000 BE0147 HM48-1 InVivoMab anti-mouse CD48 Armenian hamster IgG 1 15,000 22,000 BE0147 HM48-1 InVivoMab anti-mouse CD48 Armenian hamster IgG 5 55,000 77,000 BE0147 HM48-1 InVivoMab anti-mouse CD48 Armenian hamster IgG , ,000 BE0147 HM48-1 InVivoMab anti-mouse CD48 Armenian hamster IgG , ,000 BE0147 HM48-1 InVivoMab anti-mouse CD48 Armenian hamster IgG , ,000 BE0148 mouse Angiostatin-Ig InVivoMab recombinant mouse Angiostatin-Ig Armenian hamster IgG , ,000 BE0148 mouse Angiostatin-Ig InVivoMab recombinant mouse Angiostatin-Ig Armenian hamster IgG , ,000 BE0148 mouse Angiostatin-Ig InVivoMab recombinant mouse Angiostatin-Ig Armenian hamster IgG , ,000 BE0149 mouse Endostatin-Ig InVivoMab recombinant mouse Endostatin-Ig Armenian hamster IgG , ,000 BE0149 mouse Endostatin-Ig InVivoMab recombinant mouse Endostatin-Ig Armenian hamster IgG , ,000 BE0149 mouse Endostatin-Ig InVivoMab recombinant mouse Endostatin-Ig Armenian hamster IgG , ,000 BE0150 1D3 InVivoMab anti-mouse CD19 rat IgG2a 1 15,000 22,000 BE0150 1D3 InVivoMab anti-mouse CD19 rat IgG2a 5 55,000 77,000 BE0150 1D3 InVivoMab anti-mouse CD19 rat IgG2a , , ご注文ごとに別途取扱手数料 (2 万円 税別 ) を申し受けます
170920_BioXCell社カタログ改訂2【9校】.indd
BULK ANTIBODIES for in vivo RESEARCH Bio X Cell in vivo InVivoPlus 0.001 EU/ug 95 5 FACS ELISA 4-1BB CD137 Mouse LOB12.3 Rat IgG1 4-1BB activation BP0169 CD3 ε Mouse 145-2C11 Armenian Hamster IgG1 DP,
Immune checkpoint - CTLA-4 PD-1 2
CTLA-4 / PD-1 / PD-L1 Immune checkpoint - CTLA-4 PD-1 2 ACRO Biosystems ACRO Biosystems HEK293 Human PD-1 / PDCD1 Protein, Tag Free, Full Length PD-1 PD-1 ECD ACRO Biosystems 7 PD-1 PD-1 PD-1 His PD-1
PowerPoint プレゼンテーション
Isotype 略語紹介 AF 488 Alexa Fluor 488 AF 594 Alexa Fluor 594 AF 647 Alexa Fluor 647 AF 700 Alexa Fluor 700 BV 421 Brilliant Violet 421 BV 510 Brilliant Violet 510 BV 570 Brilliant Violet 570 BV 605 Brilliant
エピトープタグ抗体製品リスト PM020 Anti-DDDDK-tag pab Polyclonal Rabbit Ig (aff.) WB, IP, IC 100 ml 15,000 PM020-7 Anti-DDDDK-tag pab HRP-DirecT Polyclonal Rabbit I
(kda) 150 100 DDDDK-tagged protein 75 50 37 IgG Heavy chain 25 20 IgG Light chain Sample: N-terminal DDDDK-tagged β-gal protein transfectant μ μ μ http://ruo.mbl.co.jp/ エピトープタグ抗体製品リスト PM020 Anti-DDDDK-tag
2 A2B, 0/A2B IgM AF647 0 T ,000 C3/AFP IgG Annexin V AF488 0 T ,000 PE 0 T ,000 APC 2 T ,000 FITC 2 T ,000 PE 2 T 60
BD Biosciences * 2 A2B, 0/A2B IgM AF647 0 T 63776 4,000 C3/AFP IgG Annexin V AF488 0 T 6306 42,000 PE 0 T 63002 40,000 APC 2 T 602 20,000 FITC 2 T 6093 8,000 PE 2 T 60930 2,000 Alphafetoprotein 0 T 643
第１４〜１５回 Ｔ細胞を介する免疫系.pptx
MBL CD8 CD4 8.1 8.2 5.20 8.3 8.4 8.5 8.6 8.7 8.8 8.9 8.10 8.18 B7 CD28 CD28 B7 CD28 8.13 2.22 NK Toll(TLR) LBP! LPS dsrna ssrna TLR1/2/6! TLR4 TLR5 TLR3 TLR7/9 CD14! JNK/p38! MyD88! IRAK! TRAF! NFκB! TNF-α
Welcome to a ore Colorful World BD BD Horizon Brilliant Violet x 1, Lymph x 1, CD3+ CD8 PerCP-Cy5-5-A CD4+ 5 1
Brilliant Violet マルチカラー トレーニング キャンペーン BD Brilliant Violet 2 ( ) 1 ( ) P12 Brilliant Violet Welcome to a ore Colorful World BD BD Horizon Brilliant Violet x 1, 5 1 15 2 25 Lymph x 1, 5 1 15 2 25 CD3+ CD8
2つの疑問
Daiichi College of Pharmaceutical Sciences 22-1 Tamagawa-cho, Minami-ku,Fukuoka 815-8511, Japan 1. B 10 14 2 2. 1. 2. 3. G. Edelman 3. H (heavy chain) L (light chain) 2 4 S-S R. Porter papain) N Fab(Fragment
Ł½’¬24flNfix+3mm-‡½‡¹724
571 0.0 31,583 2.0 139,335 8.9 310,727 19.7 1,576,352 100.0 820 0.1 160,247 10.2 38,5012.4 5,7830.4 9,5020.6 41,7592.7 77,8174.9 46,425 2.9 381,410 24.2 1,576,352 100.0 219,332 13.9 132,444 8.4 173,450
DynalTransplantDiagnostic.indd
2011 1 SeCore HLA SBT 1 2 AllSet + Gold SSP HLA 7 3 SSP UniTray HLA 11 4 27 5 32 ii 1 SeCore HLA SBT SeCore 2 SeCore HLA SBT SeCore 3 SeCore 4 HLA-I 5 HLA-II 5 utype 5 GSSP 6 1 SeCore HLA SBT Sequencing
2001 Mg-Zn-Y LPSO(Long Period Stacking Order) Mg,,,. LPSO ( ), Mg, Zn,Y. Mg Zn, Y fcc( ) L1 2. LPSO Mg,., Mg L1 2, Zn,Y,, Y.,, Zn, Y Mg. Zn,Y., 926, 1
Mg-LPSO 2566 2016 3 2001 Mg-Zn-Y LPSO(Long Period Stacking Order) Mg,,,. LPSO ( ), Mg, Zn,Y. Mg Zn, Y fcc( ) L1 2. LPSO Mg,., Mg L1 2, Zn,Y,, Y.,, Zn, Y Mg. Zn,Y., 926, 1 1,.,,., 1 C 8, 2 A 9.., Zn,Y,.
FORES II ［フォレスII］
ORES Z7 M06 G699 MG59 M59 M49 M06 Z7 G699 1 JOIA ABS 02 231 1 2013-2014 40 -OPEN -LOK L L 1 1 L 735 A4BOX6 /653 2 601 A4BOX5 /525 257 40 2 OA 40 P252 1230 02 232 2 2013-2014 A B 9G-MP59 920RG-MP 59 106,6
I II
I II I I 8 I I 5 I 5 9 I 6 6 I 7 7 I 8 87 I 9 96 I 7 I 8 I 9 I 7 I 95 I 5 I 6 II 7 6 II 8 II 9 59 II 67 II 76 II II 9 II 8 II 5 8 II 6 58 II 7 6 II 8 8 I.., < b, b, c, k, m. k + m + c + c b + k + m log
さくらの個別指導 ( さくら教育研究所 ) A a 1 a 2 a 3 a n {a n } a 1 a n n n 1 n n 0 a n = 1 n 1 n n O n {a n } n a n α {a n } α {a
... A a a a 3 a n {a n } a a n n 3 n n n 0 a n = n n n O 3 4 5 6 n {a n } n a n α {a n } α {a n } α α {a n } a n n a n α a n = α n n 0 n = 0 3 4. ()..0.00 + (0.) n () 0. 0.0 0.00 ( 0.) n 0 0 c c c c c
untitled
0. =. =. (999). 3(983). (980). (985). (966). 3. := :=. A A. A A. := := 4 5 A B A B A B. A = B A B A B B A. A B A B, A B, B. AP { A, P } = { : A, P } = { A P }. A = {0, }, A, {0, }, {0}, {}, A {0}, {}.
第86回日本感染症学会総会学術集会後抄録（I）
κ κ κ κ κ κ μ μ β β β γ α α β β γ α β α α α γ α β β γ μ β β μ μ α ββ β β β β β β β β β β β β β β β β β β γ β μ μ μ μμ μ μ μ μ β β μ μ μ μ μ μ μ μ μ μ μ μ μ μ β
( )
18 10 01 ( ) 1 2018 4 1.1 2018............................... 4 1.2 2018......................... 5 2 2017 7 2.1 2017............................... 7 2.2 2017......................... 8 3 2016 9 3.1 2016...............................
PROSTAGE［プロステージ］
PROSTAGE & L 2 3200 650 2078 Storage system Panel system 3 esk system 2 250 22 01 125 1 2013-2014 esk System 2 L4OA V 01 2 L V L V OA 4 3240 32 2 7 4 OA P202 MG55 MG57 MG56 MJ58 MG45 MG55 MB95 Z712 MG57
ÿþ
TNF ファミリー 腫瘍壊死因子 ( Tumor Necrosis Factor: TNF) は 固形がんに対して出血性の壊死を誘導する因子として発見されたサイトカインです TNF ファミリーには TNF-α リンフォトキシンα Fas リガンドや TRAIL などのアポトーシス誘導に関与するサイトカインのほか RANK リガンド OX40 リガンド APRIL など 20 種類近くに因子が同定されています
1/68 A. 電気所 ( 発電所, 変電所, 配電塔 ) における変圧器の空き容量一覧 平成 31 年 3 月 6 日現在 < 留意事項 > (1) 空容量は目安であり 系統接続の前には 接続検討のお申込みによる詳細検討が必要となります その結果 空容量が変更となる場合があります (2) 特に記載
1/68 A. 電気所 ( 発電所, 変電所, 配電塔 ) における変圧器の空き容量一覧 平成 31 年 3 月 6 日現在 < 留意事項 > (1) 空容量は目安であり 系統接続の前には 接続検討のお申込みによる詳細検討が必要となります その結果 空容量が変更となる場合があります (2) 特に記載のない限り 熱容量を考慮した空き容量を記載しております その他の要因 ( 電圧や系統安定度など ) で連系制約が発生する場合があります
IMO 1 n, 21n n (x + 2x 1) + (x 2x 1) = A, x, (a) A = 2, (b) A = 1, (c) A = 2?, 3 a, b, c cos x a cos 2 x + b cos x + c = 0 cos 2x a
1 40 (1959 1999 ) (IMO) 41 (2000 ) WEB 1 1959 1 IMO 1 n, 21n + 4 13n + 3 2 (x + 2x 1) + (x 2x 1) = A, x, (a) A = 2, (b) A = 1, (c) A = 2?, 3 a, b, c cos x a cos 2 x + b cos x + c = 0 cos 2x a = 4, b =
2012 A, N, Z, Q, R, C
2012 A, N, Z, Q, R, C 1 2009 9 2 2011 2 3 2012 9 1 2 2 5 3 11 4 16 5 22 6 25 7 29 8 32 1 1 1.1 3 1 1 1 1 1 1? 3 3 3 3 3 3 3 1 1, 1 1 + 1 1 1+1 2 2 1 2+1 3 2 N 1.2 N (i) 2 a b a 1 b a < b a b b a a b (ii)
CRA3689A
AVIC-DRZ90 AVIC-DRZ80 2 3 4 5 66 7 88 9 10 10 10 11 12 13 14 15 1 1 0 OPEN ANGLE REMOTE WIDE SET UP AVIC-DRZ90 SOURCE OFF AV CONTROL MIC 2 16 17 1 2 0 0 1 AVIC-DRZ90 2 3 4 OPEN ANGLE REMOTE SOURCE OFF
O1-1 O1-2 O1-3 O1-4 O1-5 O1-6
O1-1 O1-2 O1-3 O1-4 O1-5 O1-6 O1-7 O1-8 O1-9 O1-10 O1-11 O1-12 O1-13 O1-14 O1-15 O1-16 O1-17 O1-18 O1-19 O1-20 O1-21 O1-22 O1-23 O1-24 O1-25 O1-26 O1-27 O1-28 O1-29 O1-30 O1-31 O1-32 O1-33 O1-34 O1-35
欧州特許庁米国特許商標庁との共通特許分類 CPC (Cooperative Patent Classification) 日本パテントデータサービス ( 株 ) 国際部 2019 年 7 月 31 日 CPC 版が発効します 原文及び詳細はCPCホームページのCPC Revision
欧州特許庁米国特許商標庁との共通特許分類 CPC (Cooperative Patent Classification) 日本パテントデータサービス ( 株 ) 国際部 2019 年 7 月 31 日 CPC 2019.08 版が発効します 原文及び詳細はCPCホームページのCPC Revisions(CPCの改訂 ) をご覧ください https://www.cooperativepatentclassification.org/cpcrevisions/noticeofchanges.html
SB-80DX SB-80DX (Jp) Jp
SB-80DX SB-80DX (Jp) Jp 2 3 4 5 6 7 k k k k k k k k k k k k k k k k 8 k k 9 k 10 k k k k k k k 11 12 13 1 5 6 2 7 8 3 4 9 10 11 12 13 14 14 1 k 8 k 2 k 9 k 3 k 10 k 4 k 5 k 11 k 6 k 12 7 k 13 14 15 16
1 911 9001030 9:00 A B C D E F G H I J K L M 1A0900 1B0900 1C0900 1D0900 1E0900 1F0900 1G0900 1H0900 1I0900 1J0900 1K0900 1L0900 1M0900 9:15 1A0915 1B0915 1C0915 1D0915 1E0915 1F0915 1G0915 1H0915 1I0915
免疫Ⅱ
100 100 100 1990 127 DNA DNA DNA DNA hybridization DNA RNA DNA DNA 128 12 µδγαε 129 300 1,200 500 50012 4 24,000 1,20024,000 2.910 7 10 8 rejection major histocompatibility complex MHC MHC MHC 130 MHC
x, y x 3 y xy 3 x 2 y + xy 2 x 3 + y 3 = x 3 y xy 3 x 2 y + xy 2 x 3 + y 3 = 15 xy (x y) (x + y) xy (x y) (x y) ( x 2 + xy + y 2) = 15 (x y)
x, y x 3 y xy 3 x 2 y + xy 2 x 3 + y 3 = 15 1 1977 x 3 y xy 3 x 2 y + xy 2 x 3 + y 3 = 15 xy (x y) (x + y) xy (x y) (x y) ( x 2 + xy + y 2) = 15 (x y) ( x 2 y + xy 2 x 2 2xy y 2) = 15 (x y) (x + y) (xy
1. 2 P 2 (x, y) 2 x y (0, 0) R 2 = {(x, y) x, y R} x, y R P = (x, y) O = (0, 0) OP ( ) OP x x, y y ( ) x v = y ( ) x 2 1 v = P = (x, y) y ( x y ) 2 (x
. P (, (0, 0 R {(,, R}, R P (, O (0, 0 OP OP, v v P (, ( (, (, { R, R} v (, (, (,, z 3 w z R 3,, z R z n R n.,..., n R n n w, t w ( z z Ke Words:. A P 3 0 B P 0 a. A P b B P 3. A π/90 B a + b c π/ 3. +
欧州特許庁米国特許商標庁との共通特許分類 CPC (Cooperative Patent Classification) 日本パテントデータサービス ( 株 ) 国際部 2019 年 1 月 17 日 CPC 版のプレ リリースが公開されました 原文及び詳細はCPCホームページの C
欧州特許庁米国特許商標庁との共通特許分類 CPC (Cooperative Patent Classification) 日本パテントデータサービス ( 株 ) 国際部 2019 年 1 月 17 日 CPC 2019.02 版のプレ リリースが公開されました 原文及び詳細はCPCホームページの CPC Revisions(CPCの改訂 ) 内のPre-releaseをご覧ください http://www.cooperativepatentclassification.org/cpcrevisions/prereleases.html
000 001
all-round catalogue vol.2 000 001 002 003 AA0102 AA0201 AA0701 AA0801 artistic brushes AA0602 AB2701 AB2702 AB2703 AB2704 AA0301 AH3001 AH3011 AH3101 AH3201 AH3111 AB3201 AB3202 AB2601 AB2602 AB0701 artistic
MACSスターティングキットの選択方法
ミルテニーバイオテク株式会社 初めての MACS スターティングキットの選択方法 初めて MACS テクノロジーによる細胞分離をお試しになる場合は スターティングキットが最適です スターティングキットは 細胞分離に 必要な機器と試薬がセットなっており 個々にご購入いただくよりも安価でご利 いただけます 多様な実験系のために 13 種類のスター ティングキットをご 意しています 選択方法に従って 最適なキットをお選びください
6. Euler x
...............................................................................3......................................... 4.4................................... 5.5......................................
iii 1 1 1 1................................ 1 2.......................... 3 3.............................. 5 4................................ 7 5................................ 9 6............................
<8DD AA97A3834C B BF8A69838A C8EA E786C7378>
ST-01738 ErythroClear Red Blood Cell Depletion Reagent kit 臍帯血 2 ml 用 17,000 13,600 ST-01739 ErythroClear Red Blood Cell Depletion kit 臍帯血 2 ml 用 475,000 380,000 ST-07801 Lymphoprep 250 ml 17,000 13,600
36 th IChO : - 3 ( ) , G O O D L U C K final 1
36 th ICh - - 5 - - : - 3 ( ) - 169 - -, - - - - - - - G D L U C K final 1 1 1.01 2 e 4.00 3 Li 6.94 4 Be 9.01 5 B 10.81 6 C 12.01 7 N 14.01 8 16.00 9 F 19.00 10 Ne 20.18 11 Na 22.99 12 Mg 24.31 Periodic
高校生の就職への数学II
II O Tped b L A TEX ε . II. 3. 4. 5. http://www.ocn.ne.jp/ oboetene/plan/ 7 9 i .......................................................................................... 3..3...............................
koji07-01.dvi
2007 I II III 1, 2, 3, 4, 5, 6, 7 5 10 19 (!) 1938 70 21? 1 1 2 1 2 2 1! 4, 5 1? 50 1 2 1 1 2 2 1?? 2 1 1, 2 1, 2 1, 2, 3,... 3 1, 2 1, 3? 2 1 3 1 2 1 1, 2 2, 3? 2 1 3 2 3 2 k,l m, n k,l m, n kn > ml...?
Lympholyte Cell Separation Media Cell Purification Immunocolumns Antibodies
Lympholyte Cell Separation Media Cell Purification Immunocolumns Antibodies Lympholyte リンパ球分離溶液 マウス / ラット / ウサギ / ヒトなどの哺乳類細胞から 生きたリンパ球を遠心により分離するための試薬です 生存リンパ球を高い収率で回収し 細胞毒性 FACS in vivo/in vitro 等の実験に使用できます
さくらの個別指導 ( さくら教育研究所 ) 1 φ = φ 1 : φ [ ] a [ ] 1 a : b a b b(a + b) b a 2 a 2 = b(a + b). b 2 ( a b ) 2 = a b a/b X 2 X 1 = 0 a/b > 0 2 a
![さくらの個別指導 ( さくら教育研究所 ) 1 φ = φ 1 : φ [ ] a [ ] 1 a : b a b b(a + b) b a 2 a 2 = b(a + b). b 2 ( a b ) 2 = a b a/b X 2 X 1 = 0 a/b > 0 2 a](/thumbs/97/131721994.jpg "さくらの個別指導 ( さくら教育研究所 ) 1 φ = φ 1 : φ [ ] a [ ] 1 a : b a b b(a + b) b a 2 a 2 = b(a + b). b 2 ( a b ) 2 = a b a/b X 2 X 1 = 0 a/b > 0 2 a")
φ + 5 2 φ : φ [ ] a [ ] a : b a b b(a + b) b a 2 a 2 b(a + b). b 2 ( a b ) 2 a b + a/b X 2 X 0 a/b > 0 2 a b + 5 2 φ φ : 2 5 5 [ ] [ ] x x x : x : x x : x x : x x 2 x 2 x 0 x ± 5 2 x x φ : φ 2 : φ ( )
熊本県数学問題正解
00 y O x Typed by L A TEX ε ( ) (00 ) 5 4 4 ( ) http://www.ocn.ne.jp/ oboetene/plan/. ( ) (009 ) ( ).. http://www.ocn.ne.jp/ oboetene/plan/eng.html 8 i i..................................... ( )0... (
R R 16 ( 3 )
(017 ) 9 4 7 ( ) ( 3 ) ( 010 ) 1 (P3) 1 11 (P4) 1 1 (P4) 1 (P15) 1 (P16) (P0) 3 (P18) 3 4 (P3) 4 3 4 31 1 5 3 5 4 6 5 9 51 9 5 9 6 9 61 9 6 α β 9 63 û 11 64 R 1 65 13 66 14 7 14 71 15 7 R R 16 http://wwwecoosaka-uacjp/~tazak/class/017
漸化式のすべてのパターンを解説しましたー高校数学の達人・河見賢司のサイト
https://www.hmg-gen.com/tuusin.html https://www.hmg-gen.com/tuusin1.html 1 2 OK 3 4 {a n } (1) a 1 = 1, a n+1 a n = 2 (2) a 1 = 3, a n+1 a n = 2n a n a n+1 a n = ( ) a n+1 a n = ( ) a n+1 a n {a n } 1,
13 0 1 1 4 11 4 12 5 13 6 2 10 21 10 22 14 3 20 31 20 32 25 33 28 4 31 41 32 42 34 43 38 5 41 51 41 52 43 53 54 6 57 61 57 62 60 70 0 Gauss a, b, c x, y f(x, y) = ax 2 + bxy + cy 2 = x y a b/2 b/2 c x
MHC23-3
Major Histocompatibility Complex 2016; 23 (3): 168 184 1) 2) 3) 4) 5) 1) 6) 7) 8) 1) 2) 3) 4) HLA 5) 6) 7) 8) HLA 11 25 28 10 22 1 4 61 44 6 1 10 11 5 HLA 60 3 27 3 5 9 5 10 19 5 50 22.4 5.9 8.2% 78.7%
190117_Quidel社カタログ改訂【初校】.indd
RESEARCH KITS AND REAGENTS Quidel 1979 1984 MicroVue 2016 3 Immutopics MicroVue 50 ISO 13485:2003 ELISA Quidel Specialty Products is the option for all your research, biosafety and cytotoxicity testing
学習の手順
NAVI 2 MAP 3 ABCD EFGH D F ABCD EFGH CD EH A ABC A BC AD ABC DBA BC//DE x 4 a //b // c x BC//DE EC AD//EF//BC x y AD DB AE EC DE//BC 5 D E AB AC BC 12cm DE 10 AP=PB=BR AQ=CQ BS CS 11 ABCD 1 C AB M BD P
> > <., vs. > x 2 x y = ax 2 + bx + c y = 0 2 ax 2 + bx + c = 0 y = 0 x ( x ) y = ax 2 + bx + c D = b 2 4ac (1) D > 0 x (2) D = 0 x (3
13 2 13.0 2 ( ) ( ) 2 13.1 ( ) ax 2 + bx + c > 0 ( a, b, c ) ( ) 275 > > 2 2 13.3 x 2 x y = ax 2 + bx + c y = 0 2 ax 2 + bx + c = 0 y = 0 x ( x ) y = ax 2 + bx + c D = b 2 4ac (1) D >
x V x x V x, x V x = x + = x +(x+x )=(x +x)+x = +x = x x = x x = x =x =(+)x =x +x = x +x x = x ( )x = x =x =(+( ))x =x +( )x = x +( )x ( )x = x x x R
V (I) () (4) (II) () (4) V K vector space V vector K scalor K C K R (I) x, y V x + y V () (x + y)+z = x +(y + z) (2) x + y = y + x (3) V x V x + = x (4) x V x + x = x V x x (II) x V, α K αx V () (α + β)x
I, II 1, A = A 4 : 6 = max{ A, } A A 10 10%
1 2006.4.17. A 3-312 tel: 092-726-4774, e-mail: hara@math.kyushu-u.ac.jp, http://www.math.kyushu-u.ac.jp/ hara/lectures/lectures-j.html Office hours: B A I ɛ-δ ɛ-δ 1. 2. A 1. 1. 2. 3. 4. 5. 2. ɛ-δ 1. ɛ-n
sekibun.dvi
a d = a + a+ (a ), e d = e, sin d = cos, (af() + bg())d = a d = log, cosd = sin, f()d + b g()d d 3 d d d d d d d ( + 3 + )d ( + )d ( 3 )d (e )d ( sin 3 cos)d g ()f (g())d = f(g()) e d e d ( )e d cos d
II Time-stamp: <05/09/30 17:14:06 waki> ii
II waki@cc.hirosaki-u.ac.jp 18 1 30 II Time-stamp: ii 1 1 1.1.................................................. 1 1.2................................................... 3 1.3..................................................
Product News (IAB)
プロダクトニュース生産終了予定商品のお知らせ発行日 2016 年 3 月 1 日 押ボタンスイッチ / 表示灯 No. 2016025C 押ボタンスイッチ形 A22 シリーズ一部商品 ツマミ形セレクタスイッチ形 A22S シリーズ一部商品 形 A22W シリーズ一部商品 キー形セレクタスイッチ形 A22K シリーズ一部商品 表示灯形 M22 シリーズ一部商品生産終了のお知らせ 生産終了予定商品 押ボタンスイッチ
A, B, C. (1) A = A. (2) A = B B = A. (3) A = B, B = C A = C. A = B. (3)., f : A B g : B C. g f : A C, A = C. 7.1, A, B,. A = B, A, A A., A, A
91 7,.,, ( ).,,.,.,. 7.1 A B, A B, A = B. 1), 1,.,. 7.1 A, B, 3. (i) A B. (ii) f : A B. (iii) A B. (i) (ii)., 6.9, (ii) (iii).,,,. 1), Ā = B.. A, Ā, Ā,. 92 7 7.2 A, B, C. (1) A = A. (2) A = B B = A. (3)
limit&derivative
- - 7 )................................................................................ 5.................................. 7.. e ).......................... 9 )..........................................
I, II 1, 2 ɛ-δ 100 A = A 4 : 6 = max{ A, } A A 10
1 2007.4.13. A 3-312 tel: 092-726-4774, e-mail: hara@math.kyushu-u.ac.jp, http://www.math.kyushu-u.ac.jp/ hara/lectures/lectures-j.html Office hours: B A I ɛ-δ ɛ-δ 1. 2. A 0. 1. 1. 2. 3. 2. ɛ-δ 1. ɛ-n
免疫学研究のための製品群
ver.1.4 The path to new discoveries From basic to clinical research in immunology Good research starts with happy cells. gentlemacs TM Octo Dissociator with Heaters TM Whole Blood MicroBeads 37 RNA Option
(1) 1 y = 2 = = b (2) 2 y = 2 = 2 = 2 + h B h h h< h 2 h
6 6.1 6.1.1 O y A y y = f() y = f() b f(b) B y f(b) f() = b f(b) f() f() = = b A f() b AB O b 6.1 2 y = 2 = 1 = 1 + h (1 + h) 2 1 2 (1 + h) 1 2h + h2 = h h(2 + h) = h = 2 + h y (1 + h) 2 1 2 O y = 2 1
(1.2) T D = 0 T = D = 30 kn 1.2 (1.4) 2F W = 0 F = W/2 = 300 kn/2 = 150 kn 1.3 (1.9) R = W 1 + W 2 = = 1100 N. (1.9) W 2 b W 1 a = 0
1 1 1.1 1.) T D = T = D = kn 1. 1.4) F W = F = W/ = kn/ = 15 kn 1. 1.9) R = W 1 + W = 6 + 5 = 11 N. 1.9) W b W 1 a = a = W /W 1 )b = 5/6) = 5 cm 1.4 AB AC P 1, P x, y x, y y x 1.4.) P sin 6 + P 1 sin 45
P14・15地域文化祭
2008 1BETSUKAI 2008.10 BETSUKAI 2008.102 3BETSUKAI 2008.10 BETSUKAI 2008.104 5BETSUKAI 2008.10 BETSUKAI 2008.106 7BETSUKAI 2008.10 BETSUKAI 2008.108 9BETSUKAI 2008.10 BETSUKAI 2008.1010 11BETSUKAI 2008.10
ALGEBRA I Hiroshi SUZUKI Department of Mathematics International Christian University
ALGEBRA I Hiroshi SUZUKI Department of Mathematics International Christian University 2004 1 1 1 2 2 1 3 3 1 4 4 1 5 5 1 6 6 1 7 7 1 8 8 1 9 9 1 10 10 1 E-mail:hsuzuki@icu.ac.jp 0 0 1 1.1 G G1 G a, b,
II (10 4 ) 1. p (x, y) (a, b) ε(x, y; a, b) 0 f (x, y) f (a, b) A, B (6.5) y = b f (x, b) f (a, b) x a = A + ε(x, b; a, b) x a 2 x a 0 A = f x (
II (1 4 ) 1. p.13 1 (x, y) (a, b) ε(x, y; a, b) f (x, y) f (a, b) A, B (6.5) y = b f (x, b) f (a, b) x a = A + ε(x, b; a, b) x a x a A = f x (a, b) y x 3 3y 3 (x, y) (, ) f (x, y) = x + y (x, y) = (, )
I ( ) ( ) (1) C z = a ρ. f(z) dz = C = = (z a) n dz C n= p 2π (ρe iθ ) n ρie iθ dθ 0 n= p { 2πiA 1 n = 1 0 n 1 (2) C f(z) n.. n f(z)dz = 2πi Re
I ( ). ( ) () a ρ. f() d ( a) n d n p π (ρe iθ ) n ρie iθ dθ n p { πia n n () f() n.. n f()d πi es f( k ) k n n. f()d n k k f()d. n f()d πi esf( k ). k I ( ). ( ) () f() p g() f() g()( ) p. f(). f() A
RN201602_cs5_0122.indd
ISSN 1349-1229 No.416 February 2016 2 SPECIAL TOPIC113 SPECIAL TOPIC 113 FACE Mykinso 113 SPECIAL TOPIC IUPAC 11320151231 RI RIBFRILAC 20039Zn30 Bi83 20047113 20054201283 113 1133 Bh107 20082009 113 113
BD = a, EA = b, BH = a, BF = b 3 EF B, EOA, BOD EF B EOA BF : AO = BE : AE, b : = BE : b, AF = BF = b BE = bb. () EF = b AF = b b. (2) EF B BOD EF : B
2000 8 3.4 p q θ = 80 B E a H F b θ/2 O θ/2 D A B E BD = a, EA = b, BH = a, BF = b 3 EF B, EOA, BOD EF B EOA BF : AO = BE : AE, b : = BE : b, AF = BF = b BE = bb. () EF = b AF = b b. (2) EF B BOD EF :
がん免疫療法モデルの概要 1. TGN1412 第 Ⅰ 相試験事件 2. がん免疫療法での動物モデルの有用性がんワクチン抗 CTLA-4 抗体抗 PD-1 抗体 2
020315 科学委員会 非臨床試験の活用に関する専門部会 ( 独 ) 医薬品医療機器総合機構会議室 資料 1 2 がん免疫療法モデルの概要 川 博嘉 1 がん免疫療法モデルの概要 1. TGN1412 第 Ⅰ 相試験事件 2. がん免疫療法での動物モデルの有用性がんワクチン抗 CTLA-4 抗体抗 PD-1 抗体 2 TGN1412 第 Ⅰ 相試験事件 2006 年 3 月 13 日英国でヒトで全く初めての物質が使用された第
1W II K =25 A (1) office(a439) (2) A4 etc. 12:00-13:30 Cafe David 1 2 TA appointment Cafe D
1W II K200 : October 6, 2004 Version : 1.2, kawahira@math.nagoa-u.ac.jp, http://www.math.nagoa-u.ac.jp/~kawahira/courses.htm TA M1, m0418c@math.nagoa-u.ac.jp TA Talor Jacobian 4 45 25 30 20 K2-1W04-00
(2016 2Q H) [ ] R 2 2 P = (a, b), Q = (c, d) Q P QP = ( ) a c b d (a c, b d) P = (a, b) O P ( ) a p = b P = (a, b) p = ( ) a b R 2 {( ) } R 2 x = x, y
![(2016 2Q H) [ ] R 2 2 P = (a, b), Q = (c, d) Q P QP = ( ) a c b d (a c, b d) P = (a, b) O P ( ) a p = b P = (a, b) p = ( ) a b R 2 {( ) } R 2 x = x, y](/thumbs/98/136512264.jpg "(2016 2Q H) [ ] R 2 2 P = (a, b), Q = (c, d) Q P QP = ( ) a c b d (a c, b d) P = (a, b) O P ( ) a p = b P = (a, b) p = ( ) a b R 2 {( ) } R 2 x = x, y")
(2016 2Q H) [ ] R 2 2 P = (a, b), Q = (c, d) Q P QP = a c b d (a c, b d) P = (a, b) O P a p = b P = (a, b) p = a b R 2 { } R 2 x = x, y R y 2 a p =, c q = b d p + a + c q = b + d q p P q a p = c R c b
空き容量一覧表（154kV以上）
1/3 A. 電気所 ( 発電所, 変電所, 配電塔 ) における変圧器の空き容量 覧 < 留意事項 > (1) 空容量は 安であり 系統接続の前には 接続検討のお申込みによる詳細検討が必要となります その結果 空容量が変更となる場合があります (2) 熱容量を考慮した空き容量を記載しております その他の要因 ( や系統安定度など ) で連系制約が発 する場合があります (3) 表 は 既に空容量がないため
0 S S 1 P MSM0 MSM0 MSM0 3 MSM03 0 MSM00 0 MSM0 MSM BP MSB0 MSB0 MSB0 MSB03 MSB00 MSB0 MSB FFPFB MSF0 MSF0 MSF0 MSF03 MSF00 MSF0 MSF C MSC0 MSC0 MSC0
S S 3 0 0 0 3 0.01MPa 1.MPa 0s 0 JIS /g 1.0 0 SMBFFBCCBTTB SPMPPFPTP TTPTBCB 1 T1S YF F 0 0 0 0 0 M SSP MP 0 3..3. 3. 0.3 0.. 1 B P 0 10 3 0 0 F FP 3 0 3 FB 3 0 3 C 0 CB 1 T TP 1 3 TB 0 0 0 1 3 1 0 0 0
…GŒÆ›u››‘KŒâ‚è_cs1.indd
1 1-1 4 1-2 a. b. c. d. e. 1-3 A. 4 B. 3 1-4 a. b. c. d. e. 1-5 1-6 4 1-7 a. b. c. d. e. 1-8 a. b. c. d. e. 1-9 1-10 A. 2 B. C. 1-11 a. / 2 b. / c. / d. / e. / 1-12 a. T b. c. M d. e. 1-13 1-14 1-15 16
2/8 一次二次当該 42 AX 変圧器 なし 43 AY 変圧器 なし 44 BA 変圧器 なし 45 BB 変圧器 なし 46 BC 変圧器 なし
1/8 A. 電気所 ( 発電所, 変電所, 配電塔 ) における変圧器の空き容量一覧 < 留意事項 > (1) 空容量は目安であり 系統接続の前には 接続検討のお申込みによる詳細検討が必要となります その結果 空容量が変更となる場合があります (2) 特に記載のない限り 熱容量を考慮した空き容量を記載しております その他の要因 ( や系統安定度など ) で連系制約が発生する場合があります (3)
X G P G (X) G BG [X, BG] S 2 2 2 S 2 2 S 2 = { (x 1, x 2, x 3 ) R 3 x 2 1 + x 2 2 + x 2 3 = 1 } R 3 S 2 S 2 v x S 2 x x v(x) T x S 2 T x S 2 S 2 x T x S 2 = { ξ R 3 x ξ } R 3 T x S 2 S 2 x x T x S 2
70 : 20 : A B (20 ) (30 ) 50 1
70 : 0 : A B (0 ) (30 ) 50 1 1 4 1.1................................................ 5 1. A............................................... 6 1.3 B............................................... 7 8.1 A...............................................
20 6 4 1 4 1.1 1.................................... 4 1.1.1.................................... 4 1.1.2 1................................ 5 1.2................................... 7 1.2.1....................................
(u(x)v(x)) = u (x)v(x) + u(x)v (x) ( ) u(x) = u (x)v(x) u(x)v (x) v(x) v(x) 2 y = g(t), t = f(x) y = g(f(x)) dy dx dy dx = dy dt dt dx., y, f, g y = f (g(x))g (x). ( (f(g(x)). ). [ ] y = e ax+b (a, b )
fpj
Folia Pharmacol. Jpn. 147 創 薬 シリーズ (8) 創薬研究の新潮流 2 高橋信明, 丹羽倫平, 中野了輔, 冨塚一磨 要約 : ADCC Potelligent 1. 抗体の構造と機能 G immunoglobulin G IgG IgG N VL CL VH CH CH CH CH CH complementarity determining region CDR CDR
研修コーナー
l l l l l l l l l l l α α β l µ l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
1 I
1 I 3 1 1.1 R x, y R x + y R x y R x, y, z, a, b R (1.1) (x + y) + z = x + (y + z) (1.2) x + y = y + x (1.3) 0 R : 0 + x = x x R (1.4) x R, 1 ( x) R : x + ( x) = 0 (1.5) (x y) z = x (y z) (1.6) x y =
untitled
2 3 4 5 6 7 (1) FC 8 (3) 1 9 2 10 3 11 4 2010P 5 6 GL GL GL 7 (2) 18 09 25 4 2010P 5 6 7 12 18 10 02 18 10 10 18 10 16 18 10 23 18 10 30 18 11 06 18 11 13 18 11 20 18 11 27 10 18 12 04 11 18 12 18 12 2010P
Z 2 10Z MPa MPa MPa MPa 1.5MPa s s s JIS 6g/6H SD SD/B LB LS
3 03 0.01MPa 0.1MPa 0.1MPa 0.01MPa 1.MPa 0s 0s 0s JIS g/h SDSD/BLB LS0 F FBTT/BTB TB/BCUCU/B SDLCFTT/B TCTC/BDBD SDSD/BLB LS0 F FBTT/BTB TB/BCUCU/B SDLBFTT/B SKSPLK LP FKFP SKSPLK LP FKFP TKTPDPBDBP TKTPDPBDBP
linearal1.dvi
19 4 30 I 1 1 11 1 12 2 13 3 131 3 132 4 133 5 134 6 14 7 2 9 21 9 211 9 212 10 213 13 214 14 22 15 221 15 222 16 223 17 224 20 3 21 31 21 32 21 33 22 34 23 341 23 342 24 343 27 344 29 35 31 351 31 352
1 1.1 H = µc i c i + c i t ijc j + 1 c i c j V ijklc k c l (1) V ijkl = V jikl = V ijlk = V jilk () t ij = t ji, V ijkl = V lkji (3) (1) V 0 H mf = µc
013 6 30 BCS 1 1.1........................ 1................................ 3 1.3............................ 3 1.4............................... 5 1.5.................................... 5 6 3 7 4 8
21 1 1 1 2 2 5 7 9 11 13 13 14 18 18 20 28 28 29 31 31 34 35 35 36 37 37 38 39 40 56 66 74 89 99 - ------ ------ -------------- ---------------- 1 10 2-2 8 5 26 ( ) 15 3 4 19 62 2,000 26 26 5 3 30 1 13
日本組織適合性学会誌第20巻2号
Major Histocompatibility Complex 2013; 20 (2): 121 129 平成 25 年度認定 HLA 検査技術者講習会テキスト HLA 1) 1) HLA HLA HLA PRA Panel reactive antibody DSA Donor specific alloantibody class subclass non-hla HLA キーワード :Human